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 Low affinity Fcγ receptor III (FcγRIII, CD16) triggers a variety of cellular events 
upon binding to the Fc portion of IgG. A real-time flow cytometry method was developed 
to measure the affinity and kinetics of such low affinity receptor/ligand interactions, 
which was shown as an easily operated yet powerful tool. Results revealed an unusual 
temperature dependence of reverse rate of CD16aTM dissociating from IgG. Except for a 
few studies using mammalian cell CD16s, most kinetics analyses use purified 
aglycosylated extracellular portion of the molecules, making it impossible to assess the 
importance of the receptor anchor and glycosylation on ligand binding. We used a 
micropipette adhesion frequency assay to demonstrate that the anchor length affects the 
forward rate and affinity of CD16s for IgG in a species specific manner, most likely 
through conformational changes. Receptor glycosylation dramatically reduced ligand 
binding by 100 folds.  
T cell receptor (TCR) is arguably the most important receptor in the adaptive 
human immune system. Together with coreceptor CD4 or CD8, TCR can discriminate 
different antigen peptides complexed with major histocompatibility complex (MHC) 
molecule (pMHC), which differ by as few as only one amino acid, and trigger different T 
cell responses. When T cell signaling was suppressed, TCR had similar affinity and 
kinetics for agonist and antagonist pMHC whose binding to CD8 was undetectable. TCR 
on activated T cell had a higher affinity for pMHCs, suggesting that TCRs organize 
themselves differently on activated T cells than on naïve T cells. In the absence of 
inhibitors for signaling, TCR binds agonist pMHC with several orders of magnitude 
higher affinity than antagonist pMHC. In addition, engagement of TCR by pMHC signals 
an upregulation of CD8 binding to pMHC, which is much stronger than the TCR-pMHC 
binding. The transition from weak TCR binding to the strong CD8 binding takes place 
around 0.75 second after TCR in contact with pMHC and can be reduced by several 
inhibitors of tyrosine and lipid phosphorylation, membrane rafts, and actin cytoskeleton. 





Low affinity Fcγ receptor III (FcγRIII, CD16) and T cell receptor (TCR) are two 
important receptors in the human immune system. Upon binding to the Fc portion of an 
IgG in an immune complex, FcγRIIIs trigger different immune responses due to different 
cell types on which they are expressed. By comparison, TCR recognizes peptide ligands 
that associated with major histocompatibility complex (MHC) molecule (pMHC).  For a 
given TCR, the pMHC ligands may act as agonist, partial agonist, antagonist and null 
based on their ability to induce T cell activation. Although differing in only a few amino 
acids, FcγRIII isoforms bind to IgG with distinct kinetic rates and affinities. In contrast to 
FcγRIII that binds to a conserved ligand (Fc portion of IgG), TCR together with its 
coreceptor, CD8, can discriminate peptides on an antigen presenting cell (APC) differing 
as few as only one amino acid to result in different outcomes for T cell activation. In this 
thesis, two aspects of the structure-function relationship of FcγRIII-IgG binding was 
characterized and the kinetics/affinities bases of TCR antigenic peptide discrimination 
were explored. Specifically, the following aims were pursued. 
 
I. To measure ligand-binding properties of Fcγ receptor III in real-time flow 
cytometry. 
II. To quantify the effects of membrane anchor and glycosylation of Fcγ receptor 
III on ligand binding affinity and kinetics. 
III. To dissect signaling independent TCR-pMHC binding kinetics. 
IV. To investigate TCR-triggered signaling-dependent rapid transition to CD8-
mediated strong adhesion. 
 






CD16 is a low affinity Fcγ receptor compared to Fcγ receptor I (CD64) and has an 
even lower affinity to soluble IgG. Several groups have studied the affinity and kinetics 
of different FcγRIII isoforms using different methods, surface plasmon resonance (SPR, 
3D), competitive inhibition assay (CI, 3D), micropipette (MP, 3D), and fluorescent 
recovery after photobleach method (FRAP, 2D). Different methods utilize different forms 
of receptors, for example, aglycosylated extracellular portion of a protein in SPR and cell 
expressed molecules in other three assays. Different methods also has their capability in 
estimate kinetics parameters, for example, CI can only estimated affinity where other 
three assays can report affinity as well as kinetics information. Therefore, developing a 
3D method that will generate both the affinity and kinetics information for a specific 
receptor ligand interaction is in need. In specific aim I, a real-time flow cytometry 
method for measuring affinity and kinetics of CD16 molecules interacting with IgG was 
developed. Two protocols were developed, association and dissociation, and their 
application on CD16aTM, CD16bNA2 were compared. Real-time flow cytometry was also 
used to study temperature effect on receptor/ligand binding. Results show that real-time 
flow cytometry is an easy operated yet powerful protocol in studying low affinity 
receptor/ligand binding. The affinity and kinetics parameters we acquired are in good 
agreement with other measurements.  
As discussed above, most published data regarding CD16 ligand binding 
measured in 3D neglect the effect of protein anchor and glycosylation. Previously it has 
been shown in micropipette assay that cell expressed CD16s with different membrane 
anchors bind ligand with different affinities regardless of the same extracellular sequence. 
Molecules with different anchors may have different diffusion rate on cell membrane, 
which may influence kinetic measurement. Therefore, to compare the anchor effect in a 
cleaner background, we now show that soluble CD16s (sCD16) isotypes with different 
anchor truncation of bind to human IgG1 (hIgG1) with different affinity and they are 
correlated with anchoring length in specific aim II. This trend is inversed when the ligand 
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is changed from hIgG1 to mouse IgG2a (mIgG2a). Resulted data suggest a 
conformational change on receptor anchor, which is distal to ligand binding epitope, 
could affect ligand binding and this effect varied with different ligand used. Effect of 
receptor glycosylation was also studied by comparing affinities of glycosylated CHO 
CD16 and aglycosylated CHO CD16 isotypes (aglycosylated receptor was generated by 
supplementing culture medium with tunicamycin to block the synthesis of N-
glycosylation) binding to hIgG1. Results show that receptor glycosylation will 
dramatically inhibit ligand binding by 100 folds suggesting sugar moieties close to ligand 
binding pocket will destabilize ligand binding and resulted a much smaller affinity 
compared to aglycosylated receptor. 
TCR/pMHC interaction is another type of weak adhesion. Their affinity and 
kinetics measurement were impossible until the merge of SPR. In SPR measurement, it is 
required that either purified receptor or ligand was immobilized on sensor chip. However, 
experiments have shown that activated T cells react to pMHC better than naïve T cells. 
This difference could result from that TCRs organize them differently on activated T 
cells than naïve T cells. Micropipette adhesion assay using receptors reside in their native 
environment and it allows us explore this difference. In specific aim III, TCR on both 
activated T cells and naïve T cells interacting with four different pMHC were tested. 
Their affinity and kinetics were compared. Results show that TCR on activated T cell has 
a higher affinity toward pMHC. Though trigger different biological out comes, agonist 
pMHC and antagonist pMHC have similar affinity and kinetics.  
 Upon engagement to pMHC, TCR recognize different antigenic peptides that 
incorporated to MHC and generate distinct signal. Together with its coreceptor and other 
accessory molecules, they will orchestrate different response to antigen. Over the past 
several years, significant advances have been made in elucidating the molecular details of 
signal cascades upon TCR activation. Recent discovery of immunological synapse and 
applications of different fluorescent microscopic technology have brought us colorful and 
live pictures of what is happening on the T cell/APC contact. However, due to the 
tempera resolution, event that happens in the first several seconds after T cell in contact 
with an APC is still not well defined. In specific aim IV, we use micropipette adhesion 
assay to explore the initial contact of a T cell and a pMHC decorated RBC. In 
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physiological condition, results show that T cell will develop aggravated adhesion 
towards agonist-MHC on RBC but not other pMHCs. This adhesion is mediated by TCR-
CD8/pMHC only and is independent of other molecules. We further show that, this 
change in adhesion mode happens around 0.75 second after TCR in contact with pMHC 
and can be completely blocked by CD8 blocking antibody and can be reduced by 
inhibiting protein tyrosine kinase (PTK) activation and disrupting actin polymerization. 
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 CHAPTER III 
BACKGROUND 
 
Cell-cell interaction is a very important step in many biological processes, 
including embryo development, wound healing, immune response and many other 
aspects of maintaining a healthy living being. This interaction is mostly initiated by a 
group of specialized proteins on the cell membrane, called receptors, interact with 
another group of proteins, called ligands. Ligands can be either soluble proteins secreted 
by other cells or proteins on another cell membrane. Like other proteins, each receptor 
and its ligand have a unique structure that dictates their recognition between them to be 
very specific. Once a receptor recognizes its ligand from a pool of proteins, it usually 
generates a signal to alert cell to response to the outside environment. Take human 
immune system as an example; many cells have the ability to launch a killing sequence 
based on the signals sent by their surface receptors. In the innate immune system, ligand 
binding to Toll-like receptors (TLR) on macrophages and dendritic cells can direct host 
the cell to engulf pathogens. Ligand binding to Fcγ receptors (FcγR) on neutrophils can 
coordinate the cell to phagocytose immune complexes (IC). In the adaptive immune 
system, ligation of T cell receptors (TCR) on cytotoxic T cell with its ligand enables T 
cell to directly secrete toxic molecules to its target cell. In this thesis, the kinetics of 
FcγRIII and TCR binding to their respective ligands were analyzed.  
 
Fcγ Receptors 
Fc receptors (FcRs) recognize the Fc portion of antibodies either in soluble state 
or as part of an immune complex. Five different types of FcRs recognize different 
immunoglobulins (Ig) [1-3]. Fcγ receptors (FcγRs) recognize Fc portion of the IgG. They 
are expressed on almost all the hematopoietic cells. Multivalent binding of FcγR to IgG 
in immune complex or opsonized particles triggers different cellular reactions depending 
on the Fcγ receptors class and isotype as well as the cells on which they expressed. There 
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are three subclasses of FcγRs, Fcγ receptor I (FcγRI, CD64), Fcγ receptor II (FcγRII, 
CD32), and Fcγ receptor III (FcγRIII, CD16). CD64 is a high affinity Fcγ receptor (KA ~ 
10-9M-1), whereas CD32 and CD16 are low affinity Fcγ receptors (KA ~ 10-6M-1) [4, 5].  
For the phagocyte, the activation of FcγRs can trigger a spectrum of integrated cell 
programs including oxidative burst, secretion of intracellular granule contents, cellular 
cytotoxicity, gene activation with new protein synthesis, and release of various cytokines 
[6]. The FcγRs on B lymphocytes can provide negative regulatory signals, and in the 
context of autoimmunity, modulation of B cell hyperactivity stands out as a potential 
therapeutic target [7]. FcγRs are also found on some γ/δ T cells and are transiently 
expressed during thymic development [7]. FcγRs on natural killer (NK) cells mediate 
antibody-dependent cellular cytotoxicity [8]. 
 
Structures and Functions of FcγRIII 
CD16 is encoded by two genes, gene A and gene B, which give two different 
protein products, CD16a and CD16b. CD16a is expressed on macrophages, mast cells, 
and natural killer cells as a transmembrane receptor. However, it does not contain any 
signal motif. As compensation, it associates with a hemo- or hetero-dimeric γ and/or ζ 
chains, which contain immunoreceptor tyrosine-based activation motif (ITAM) [9, 10] 
that is rich in tyrosine phosphorylation sites in its cytoplasma domaim. The absence of γ 
and ζ leads to the loss of surface expression of CD16a [11]. Present exclusively on 
neutrophils, CD16b is the only Fc receptor anchored by a glycosyl-phosphatidylinositol 
(GPI) linker to the plasma membrane. CD16b has two alleles, CD16bNA1 and CD16bNA2.  
Despite the lack of a signaling component, CD16b plays an active role in triggering Ca2+ 
mobilization and neutrophil degranulation [12, 13]. In addition, in conjunction with 
FcγRIIa, FcγRIIIb activates phagocytosis, degranulation, and oxidative burst, which lead 
to the clearance of opsonized pathogens by neutrophils. Recently, a soluble form of 
FcγRIIIb was reported to activate the complement receptor CR3-dependent inflammatory 
process [14].  
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Figure 3-1. Structure differences within CD16aWT, CD16bNA1and CD16bNA2. 
 
Figure 3-1 shows one mutant CD16aGPI that has a GPI anchor instead of a 
transmembrane domain and the three different wild types CD16 molecules, CD16aTM that 
is associated with γ and ζ chains, CD16bNA1 and CD16bNA2 that have GPI anchors and do 
not associate with γ and ζ chains. All these CD16 molecules are composed of two Ig-like 
globules with the glycosylation sites shown as sticks. The extracellular domain amino 
acids that differ among the three CD16 isoforms are listed. Compared to those on CD16a, 
the different amino acids on CD16b are underlined, while the differences between the 
two CD16b alleles are shown in italic. Early experiments using fusion proteins, single-
residue mutation and antibody mapping, show that the ligand binding site of CD16 is 
located at the second, membrane-proximal, Ig-like globule [15-18]. In addition, studies 
suggested mutants with amino acids Q143-Y150 replaced by alanine one by one greatly 
decreased IgG binding, except for mutant D147A, which increased the binding by more 
than twofold [16].  
The first crystal structure of FcγRIIIb was solved in 2000 [19]. An acute 
interdomain hinge angle of approximately 50° was observed. The putative Fc binding 
region of the receptor carries a net positive charge complementary to the negative-
charged receptor binding regions on Fc. Later, crystal structures of FcγRIIIb in complex 
with human IgG Fc were published by two groups independently [20, 21]. Although the 
crystals obtained by the two groups have different space group symmetried, the 
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superposition of two structures resulted in a root mean square (r.m.s.) deviation of 0.5 Å 
for all Cα atoms. Both groups found that sFcγRIIIb has the characteristic heart-shaped 
domain arrangement described for sFcγRIIb and other sFcRs. Compared with the stand 
alone structure, the sFcγRIIIb molecule displays an opening of its interdomain angle for 
10° where it is in complex with hIgG1 Fc. The horseshoe shaped hFc1 molecule also 
opens. The contact interface between sFcγRIIIb and hFc1 consists mainly of van der 
Waals interaction on Cγ2-A (Cγ2-B in P. Sun’s paper) of Fc and hydrogen bonds and salt 
bridges on Cγ2-B (Cγ2-A in P. Sun’s paper) of Fc. Such binding breaks down the 
symmetry of the Fc, creating an asymmetric interface whereby the identical residues from 
Hinge-A and Hinge-B interact with different, unrelated surfaces of the receptor.  
 
Figure 3-2. The overall structure of the sFcγRIII-hFc1 complex (adapted from 
Sondermann P., et al, Nature, 2000). 
 
In order to characterize the IgG binding of FcγRIIIs, aglycosylated soluble CD16s 
produced by E. coli. have used to measure their affinities and kinetics using surface 
plasma resonance (SPR, for example, with the commonly used instrument BIAcore®). 
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SPR technique measures the mass concentration of proteins (refractive index) in close 
proximity to a specially prepared surface. It requires immobilization of one of the 
interacting molecules onto a sensor surface allowing the other binder molecules to flow 
over it; in this way, the real-time binding is detected. Proteins synthesized by E. coli. do 
not have sugar moiety attached to their amino residues due to the lack of post-
translational enzymes. However, Jeffrey C. Edberg and colleagues have shown that 
CD16a molecules expressed on NK cell and monocyte have different affinities to their 
ligand due to differential cell type-specific glycosylation, although they have identical 
protein cores. These results indicate that natural glycoforms of FcγRIIIa (cell type-
specific glycosylation variants) bind ligand differently, conferring a lower affinity on 
monocyte/macrophage FcγRIIIa, which makes the receptor ideal for initial immune 
complex capture and sensitive to moderate changes in serum IgG levels [22]. More recent 
mutagenesis results have shown that monomeric IgG bound to N163Q transfectants with 
higher affinity than to other transfectantas, suggesting that (N)-linked glycosylation in 
asparagines 163, which is located in ligand binding pocket, influences the affinity of 
CD16 for its ligand. In addition, preincubatyion of wild-type CD16 transfected cells with 
Tunicamycin (an inhibitor of N-glycosylation) resulted in an increased binding of 
monomeric IgG whereas N163Q-CD16-transfected cells remained unaffected. Therefore, 
glycosylation in N163 is a mechanism of regulation for affinity of FcγRIII for its ligand 
IgG. [23]. The importance of post-translation process is also observed in other molecular 
system, such as CD8, where non-sialylated glycoforms are present in immature 
thymocytes but are virtually absent in mature thymocytes. This glycosylation difference 
is linked to ligand binding affinity difference between CD8 on mature and immature 
thymocytes [24]. 
Chesla et al. have previously reported kinetic rates and affinity on human CD16s 
expressed on CHO cells, CD16a-TM, CD16bNA1, CD16bNA2, and CD16aGPI (figure 3-1) 
[25]. The results showed that anchor influenced kinetics and affinity. Compared with 
CD16aTM, CD16aGPI bound faster with higher affinity to human and rabbit IgGs but 
slower with lower affinity to murine IgG2a. It was suggested that the membrane anchor 
influenced ligand binding of CD16 by conformational change. However, the anchor 
effect has not been well appreciated in receptor-ligand binding partly because affinity and 
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kinetics measurement of such a weak interaction, like FcγRIII, is not available until 
recent application of the SPR technology. Almost all SPR measurements used molecules 
that are produced by E. Coli, which can be used to produce milligram quantity to satisfy 
the instrumentation requirement. However, molecules that generated this way only 
contain receptor’s extracellular domain, which has been a limitation in exploring the 
anchor effect on ligand binding kinetics of a molecule. Another reason of slow progress 
in this area is the lacks of molecular structure of transmembrane and GPI anchors. Again, 
almost all X-ray crystal structures of membrane proteins only contain the extracellular 
domain because it is very difficult to purify milligram quantity of membrane protein from 
mammalian cells and it is even harder to crystallize proteins with their nature anchor. 
However, anchoring effect in ligand binding has been seen on another receptor. Thy-1 
protein, a member of the Ig superfamily, is bound to the cell membrane by a GPI anchor. 
It has been shown that following anchor cleavage by phospholipase C, the reactivity of 
the solubilized Thy-1 with several mAbs is lost, and its reactivity with polyclonal anti-
Thy-1 Abs is markedly decreased. These results suggest that the marked decrease in Thy-
1 immunoreactivity following delipidation is due to conformational changes in the Thy-1 
protein after anchor truncation [26].  
 
T Cells 
T lymphocytes are one of the most important cells in the human immune system 
responsible for the adaptive immune response. They originate from bone marrow and 
mature in the thymus, and hence acquire the name T cell. When T cells mature, they 
differentiate into two distinct lineages that can be distinguished by their expression of 
CD4 or CD8 membrane molecules. Helper T (TH) cells are usually identified by the 
presence of the cell-surface molecules CD4. Cytotoxic T (TC) cells express CD8 
molecules. As their name indicated, TH cells help B cells and other T cells to multiply 
into large clones and carry out their role in the immune response. TH cells enhance B cell 
antibody production, macrophage activation, and TC cell differentiation. TC cells are 
responsible for killing virus-infected cells, transplanted tissue, and cancer cells. TC cells 
kill a target cell either by latching onto the target cell’s surface and injecting a 
membrane-disrupting agent perforin or by a mechanism involving the engagement of the 
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Fas cell-surface molecules, which leads to apoptosis of the target cell. The present project 
focuses on TC cells. 
 
TCR, MHC Molecules and Co-receptors 
Unlike B cells which use cell bound antibody (B cell antigen receptor, BCR) to 
recognize an antigen in its intact protein state, T cells can recognize an antigen only after 
the antigen has been broken down from protein to a small peptide (8-15 amino acid in 
length) and presented by a major histocompatibility complex (MHC) molecule. Virtually 
every cell in the body expresses MHC molecules. Three MHC genes encode three classes 
of molecules that are essential for T cell functions. Class I region genes encode MHC 
class I (MHC-I) molecules, which are expressed on the surface of almost all nucleated 
cells and which present peptide antigen to TC cells. Class II region genes encode MHC 
class II (MHC-II) molecules, which are expressed primarily on antigen-presenting cells 
(APCs; macrophages, dendritic cells, B cells, Langerhans cells of the skin, and human 
endothelial cells) and which present peptide antigen to TH cells. Class III (MHC-III) 
region genes encode class III molecules, the complement proteins, and other proteins 
unrelated to MHC class I and class II molecules [27]. MHC-I molecules are the focus of 
the present project. 
The antigenic peptide presented by MHC molecules is recognized by TCR. TCR 
is a heterodimeric molecule composed of either α and β or γ and δ chains. These two 
chains are held together by a disulfide bond; they are built with the Ig fold as their 
backbone structure. TCR is also non-covalently associated with two ζ chains and CD3 
which contains ε, δ, γ and η chains [28]. Similar to FcγR, the absence of CD3 and ζ 
chains leads to the loss of surface expression of TCR [29]. CD3 and ζ chains contain 
ITAM, which will transmit signals after TCR ligantion with antigen. This requires 
TCR/peptide-MHC (pMHC) interaction as well as co-receptors, CD4 or CD8.  
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Figure 3-3. Schematic drawing of early signaling events in T cells (adapted from 
Okkenhaug et al., Nat. Rev. Immunol., 2003). 
 
Another molecule that also recognizes class I MHC is the coreceptor CD8 that is 
expressed on the TC cell surface as either an αα homodimer or an αβ heterodimer. Either 
α or β chain of CD8 consists of four discrete functional domains that can be related to the 
primary sequence as follows: the Ig-like extracellular domain, the membrane proximal 
stalk (hinge) region, the transmembrane domain and the cytoplasmic domain. Recently 
available crystal structure shows that the Ig-like domain is involved in the binding to 
pMHC [30, 31].  Fewer studies have focused on the interaction between coreceptors and 
pMHC than those between TCR and pMHC binding. Significant discrepancies exist 
among the in vitro data generated in different studies using soluble molecules [32]. 
There are more than half a dozen crystal structures of αβ TCRs complexed to 
their cognate antigenic pMHC ligands. Those include both class I [33-36] and class II 
complexes [37, 38]. These data in general support a common docking mode of TCRs 
towards the pMHC complex [39-42]. The overall topology of the docking mode is such 
that the Vα domain of the TCR is closest to the N-terminal residues of the antigenic 
peptide whereas the Vβ domain of the TCR is closest to the C-terminal segment of the 
peptide. This conservation also mandates that the TCR Vβ domain contacts the MHC α1 
domain, while the TCR Vα domain interacts with the other domain of the MHC antigen-
resenting platform (α2 for MHC-I or β1 for MHC-II).  
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Figure 3-4. Structure of the BM3.3 TCR–pBM1–H-2Kb complex (adapted from Reisei et 
al., Nat Immunol, 2000).  
 
How TCR and the co-receptor coordinate this bidentate interaction and 
subsequent downstream signaling is of particular interest. Structures of the interacting 
ectodomains of both CD8 [43] and CD4 [44-46] are known. In addition, the binary 
complex structures of the CD8αα homodimeric Ig-like domains bound to pMHC-I for 
human and mouse have been defined [30, 31]. Very recently the crystal structure of a 
CD4 two domain (D1D2) fragment complexed to a pMHC-II has also been determined 
[47]. Unexpectedly, the way CD4 binds to pMHC-II is quite different from that of CD8 
to pMHC-I. CD8αα binds to the pMHC-I molecule in a manner analogous to the way in 
which an antibody interacts with antigen using its CDR-like loops. In fact, in the 
CD8αα–pMHC-I interaction, all six CDR-like loops from the two CD8 monomers clamp 
down onto the protruding CD loop of the MHC-I molecule’s α3 domain. Additional 
contacts with MHC-I α3 itself, β2-microglobulin (β2M) and, to a small extent, MHC-I α2 
have been defined [31]. By contrast, CD4 uses its N-terminal domain’s “top corner” to 
reach the domain junction between MHC-II α2 and β2 domains without directly 
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contacting the corresponding CD loop on the β2M. The CD4 binding does not seem to 
cause noticeable conformational change of pMHC-II, as if the α2 and β2 domains of 
MHCII were pre-configured for CD4 binding. This situation contrasts with that of CD8–
pMHC-I ligation, which is associated with a swing of the α3 domain of pMHC-I upon 
CD8 binding [30, 31]. To date, the biological significance of the α3 domain movement is 
unresolved. 
 
Figure 3-5. Comparative ribbon drawings of the complex structures between an MHC 
molecule and its respective co-receptor. Left, the CD8αα homodimer (in red and 
magenta) complexed to murine MHC-I H-2Kb (cyan for α chain and green for β2 chain) 
is shown. Right, the CD4 first two domain (in magenta) is shown complexed to murine 
MHCII I-Ak (cyan for α chain and green for β chain). Note how the CD8 dimer clamps 
down on the CD loop of MHC’s α3 domain, whereas CD4 uses its top corner to reach the 
domain junction between MHC’s α2 and β2 (adapted from Wang, J.H., et al., Proc Natl 
Acad Sci U S A, 2001). 
 
Signal Transduction in TCR 
TCR does not have signaling motif itself and has to associate with ITAM 
containing proteins, such as CD3 and ζ chains. TCR initiates signaling by recruiting and 
activating protein tyrosine kinases (PTK) of the Src, Syk and Tec families [48-50]. 
Immunoreceptor tyrosine-based activation motifs (ITAM) of the signal transducing 
antigen receptor subunits (CD3 and ζ) are phosphorylated by Src PTK (probably Lck in T 
cells) thus allowing the Syk family PTK ZAP70 to bind to the ITAM via its tandem Src-
homology 2 (SH2) domains. ITAM-bound ZAP70 is then tyrosine phosphorylated and 
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activated, leading to the phosphorylation of ZAP70 substrates such as the adaptors SLP76 
(SH2 domain containing lymphocyte protein of 76,000 MW) and LAT (linker of 
activated T cells) [50-52]. These adapters form scaffolds to assemble signal tranduction 
molecules in the correct intracellular location for them to execute their effector function 
either directly or after allosteric regulation by co-assembled regulatory proteins. Tyrosine 
phosphorylation of adaptors links antigen receptors to a cascade of signaling pathways 
during T-cell activation; the key ones are the activation of Ras and Rho-family GTPases, 
MAPK cascades [53-55], phosphatidylinositol 3 kinase (PI-3 kinase) [56-59], PKCθ [60, 
61], and the NF-κB pathway [62-64]. In addition, TCR ligation leads to the 
phosphorylation and activation of PLC-γ1, which initiates inositolphospholipid (IP) 
turnover and intracellular free ionized calcium ([Ca2+]i ) flux [65-68]. A summation of 
these effects leads to transcriptional activation of biologically important genes.  
 
Phosphoinositide 3-kinases 
Phosphoinositide 3-kinases (PI3Ks) regulate numerous biological processes, 
including cell growth, differentiation, survival, proliferation, migration and metabolism. 
Based on structure similarities, the PI3K family can be subdivided into three classes — 
class I, class II and class III. The class I PI3Ks are subdivided into two groups — the 
class IA and class IB PI3Ks. The class IA PI3Ks are activated by tyrosine-kinase-
associated receptors, including antigen, co-stimulatory and cytokine receptors. The class 
IB PI3K, PI3Kγ, is activated by G-protein-coupled receptors (GPCRs) — a large family 
of receptor proteins that includes the chemokine receptors. Little is known about the role 
of class II and class III PI3Ks in lymphocytes [69, 70]. The class IA PI3Ks are the focus 
of this thesis. 
Class IA PI3Ks are heterodimeric enzymes consisting of a regulatory subunit 
(p85α, p85β or p85γ) and a catalytic subunit (p110α, p110β or p110δ). Each of the 
catalytic subunits can associate with all of the regulatory subunits. The function of class I 
PI3Ks is to phosphorylate the D-3 position of the inositol head group of the 
phosphatidylinositol-(4,5)-bisphosphate (PtdIns(4,5)P2) to produce phosphatidylinositol-
(3,4,5)-trisphosphate (PtdIns(3,4,5)P3) at the inner leaflet of the plasma membrane. 
PtdIns(3,4,5)P3 binds to numerous intracellular enzymes that contain pleckstrin-
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homology domains (PH domains) [71, 72] and reported to occur in response to ligation of 
several surface molecules involved in T-cell activation and proliferation, including the T-
cell receptor [56], CD28 [73], CTLA-4 [74], CD2 [56] and CD4 [57, 75], which 
modulate the early events in T-cell activation. Use of the pharmacological PI3K 
inhibitors wortmannin and LY294002, gene knockout and many other methods has 
identified that PI3K products interact with many different types of signaling products. 
They are the TEC family of tyrosine kinases which include Itk, Tec and Btk [76, 77], 
GTPases which include Rac and Rho [78, 79], and perhaps the most important of these is 
the serine/threonine kinase AKT/PKB, which has an important role in cell proliferation, 
growth, survival and metabolism in many cell types, and the role of which is conserved 
through evolution [80-82]. Recently, Harriague et al. used mouse CD4 T cell hybridoma 
and human peripheral resting CD4 T cells to show that as early as 100 second after 
placing T cells and APC in contact, Akt was highly enriched at the contact zone. Neither 
the formation of conjugates between T cells and APCs nor signaling events such as 
phosphotyrosine accumulation and calcium increase changed substantially when PI3K 
was inhibited. They also found that PIP3 accumulated at the T cell-APC synapse as well 
as in the rest of the T cell plasma membrane [59]. About the same time, Costello et al. 
used mouse transgenic CD8 naïve T cells, P14 and F5, to show that production of 
PtdIns(3,4,5)P3 was dynamically sustained for hours as T cells responded to antigen. In 
addition, sustained elevation of PtdIns(3,4,5)P3 was essential for T cell proliferation. 
They also found that PtdIns(3,4,5)P3 accumulation in the T cell-APC contact zone as well 
as at the antipodal pole of the cell. The immunue synapse is thus not the sole site of 
sustained signal transduction in activated T cells [58].  
 
Mechanism of TCR Triggering 
TCR Repertoires Diversity 
By gene rearrangement, TCR diversity greatly exceeds Ig diversity. Each T cell 
expresses only one clone of TCR. Not only can TCR tell self peptides from nonself 
peptides, but it can also discriminate agonist (strong activating), partial agonist (weak 
activating), null (nonresponsive) and antagonist (inhibitory) peptides within nonself 
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peptides [83]. All these four peptides have the same amino acid length and differ as little 
as only one residual. Furthermore, TCR recognizes an antigenic peptide from a sea of self 
peptides presented by the same MHC molecules at the same time on the same target cell 
surface. Studies have shown that as low as few tens of specific peptide-MHCs are enough 
to fully activate the T cell [84-86]. Exactly how TCR is activated is still a hotly debated 
issue in immunology. 
 
Models for TCR Antigenic Peptide Recognition 
Soon after the TCR was discovered, researchers started to propose models and 
tried to elucidate the mechanism for TCR antigenic peptide discrimination. These include 
affinity model [87], conformational change model [88, 89], dimerization or 
oligomerization model [90, 91], kinetic proof-reading [92] or kinetic discrimination 
model [93], and kinetic/segregation model [94, 95] etc. Conformational change is 
commonly seen in enzyme-substrate interaction. But no evidence has been found from 
crystallographic studies to support the conformational change model for TCR. 
Dimerization or oligomerization is a common strategy used by numerous growth factor 
receptors, cytokine receptors and FcγR, but using chemically cross-linked MHC 
molecules to induce oligomerization of TCR either on cell surface or in solution only 
provides indirect evidence. In two studies, direct evidence has been reported that TCR 
also uses dimerization or oligomerization as signaling method. But when Baker and 
Wiley tried to repeat this experiment, they could not obtain the same results[96]. The 
affinity model argues that TCR-pMHC binding affinity is the key parameter that 
regulates the TCR activation. It is hard to envision how a little variation of affinity among 
the different peptide-MHCs interacting with the same TCR may give rise to a huge 
variation in cellular responses. Kinetic proof-reading and kinetic discrimination models 
suggested that kinetics, especially the dissociation rate constant, which differs a lot 
among variant peptide-MHC interacting with the same TCR, is the key regulator. The 
kinetic/segregation model further extends the kinetic proof-reading or kinetic 
discrimination model. It proposes that the segregation induced by kinetic difference 
between TCR and different peptide-MHC is the determinant for TCR triggering.  Recent 
emerged peptide stability model highlight the interaction between peptide and MHC as an 
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important factor in determining the outcome of TCR. In this model, partial agonist can be 
generated through changing peptide affinity for MHC [97]. All these arguments are 
focused on the affinity and kinetics of TCR binding to peptide-MHC. Therefore, studying 
the TCR/peptide-MHC/CD8 interaction, especially the 2D kinetics, will provide useful 
information for the understanding of the mechanism of T cell antigenic peptide 
discrimination. This is the main approach of the present thesis. 
 
Role of CD8 in T cell activation 
Unlike FcγRs which can induce full cell response by its own, the full activation of 
a T cell cannot be fulfilled by the interaction of TCR with peptide-MHC alone. Other 
molecular interactions, such as co-receptor CD4 and CD8 binding to MHC, adhesion 
molecule CD2 binding to its counter receptor CD58 (CD48 in mouse) [94, 98, 99], 
costimulatory molecules CD28 interacting with CD80/CD86 [100] are actively involved 
in this process (Figure 3-6).  
 
Figure 3-6. TCR and accessory molecules interacting with counterpart ligands on APC in 
immune synapse. [101] 
 
Kinetics and Affinities of CD8-pMHC Interactions 
 The binding of CD8aa to pMHC was initially demonstrated by using cell–cell 
adhesion assays [102-104]. In recent years, SPR has proved to be a reliable method for 
measuring the affinity and kinetics of very weak protein–protein interactions such as 
CD8–pMHC and TCR–pMHC [98]. The binding of CD8 to pMHC is extremely weak 
[Kd = 90–220 μM [105]; 11–40 μM [106]; 22–86 μM [107]; 100 μM [108] and 140-200 
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μM [109]], with significantly lower affinities than those characterizing TCR–pMHC 
interactions (1–50 μM at 25°C) [110] or those characterizing typical adhesion molecule 
interactions (for example, CD2 and CD48, 30–50 μM at 25°C) [98]. However, the most 
striking feature of the CD8–pMHC interaction is its extremely fast kinetics (dissociation 
rate constant, koff ≥ 18 s-1 [105]) compared with TCR–pMHC interactions (koff ranging 
from 0.01–0.1 s-1 for agonist peptide pMHC [110]). It is so fast that the direct 
measurement of the association rate constant (kon) is impossible. These extremely fast 
kinetics have been observed in both the human and mouse CD8–pMHC complex 
interactions [105]. These results indicate that the affinity of CD8-pMHC interaction is 
only slightly dependent on species or allele type. The transient nature of the CD8–pMHC 
interaction supports the notion that T-cell activation involves binding of CD8 and TCR to 
the same pMHC molecules (with the TCR dominating the interaction).  
 
Cooperativity in pMHC Binding between CD8 and TCR 
 Experiments involving soluble mouse CD8, TCR and MHC molecules have 
suggested that CD8 enhances binding of TCR to the pMHC complex through a reduced 
“off” rate and this effect is independent of haplotype and peptide content. However, using 
human proteins, Wyer et al. have revealed that the TCR binding and dissociation time-
course were independent of the presence of CD8 molecules in the reaction mixture. 
Based on these observations the authors concluded that there is no cooperativity in CD8 
and TCR interactions with their pMHC ligand, i.e., CD8-pMHC interaction does not 
affect the affinity of the TCR-pMHC interaction, and CD8 and TCR bind the antigen 
independently. This however does dot exclude the possibility of CD8 involvement in 
pMHC binding on the cell-surface that can influence the process in a different way. 
 
CD8 Modulation of TCR-pMHC Interaction on Live Cells 
Mescher’s group has shown that upon the addition of anti-TCR mAb in solution 
(fluid-phase), where only bivalent cross-linking of the TCR is presumed to occur, CTL 
are stimulated to undergo CD8-dependent adhesion to class I MHC. CTL binding to 
irrelevant class I MHC could also be achieved by this TCR cross-linking method and can 
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be blocked by CD8 antibody too [111]. They further show that this CD8-dependent 
adhesion of CTL to Class I MHC is sensitive to cytoskeleton disruption agents 
cytochalasin D and E and colchicines [112]. Furthermore, fluid phase anti-TCR mAb is 
not a sufficient stimulus to initiate PI hydrolysis or cause and increase in [Ca2+]j, but 
these events are activated when cells undergo CD8-dependent adhesion to class I MHC 
[111, 113, 114]. TCR-dependent activation of CD8 requires protein tyrosine 
phosphorylation, as shown by the ability of herbimycin A and genistein to inhibit 
triggered adhesion to class I MHC [114]. Recently the same group used wortmannin, a 
potent PI3 kinase inhibitor, blocks TCR-signaled activation of CD8-mediated adhesion to 
class I MHC protein [115]. Other groups also found that TCR-ligand interaction on CTL 
is greatly strengthened by CD8. Using CD8+ and CD8- CTL clones, Luescher et al. found 
that monomeric Kd molecules photoaffinity labels better on CD8+ cells than CD8- cells 
and the differential binding can be reduced by over 95% in the presence of anti-CD8 
antibody. Substitution of Kd Asp 227 with Lys in the soluble ligand resulted in a more 
than 80% reduction of the TCR labeling on CD8+ cells but had no detectable effect on the 
labeling of CD8- cells [116]. Similar results have been obtained using monomeric pMHC 
as a ligand. Under this condition, Ca2+ responses can only be observed in CD8+ cells, not 
when either the CD8:MHC or CD8:Lck interactions are prevented. This demonstrates 
that an intact CD8 coreceptor is necessary for effective TCR signaling in response to 
monomeric peptide-MHC molecules [117].  
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CHAPTER IV 
MATERIALS AND METHODS 
 
Cell 
CHO cells transfected to express CD16aTM, CD16aGPI, CD16bNA2 and B7-1-
CD59, as well as nontransfected CHO cells, were kind gifts of Dr. P. Selvaraj, Emory 
University School of Medicine. Macrophages from Tap knockout mice and naïve F5 T 
cells purified from spleen of F5 transgenic mice were kindly provided by Dr. S. 
Sambhara from CDC.  Naïve and activated 2C T cells were provided by Dr. Jonathan 
Schneck of the Johns Hopkins University. Erythrocytes were isolated from the whole 
blood of normal healthy volunteers. 
Antibodies 
The murine monoclonal antibody 214.1 (anti-CD16, capture antibody) was 
provided by Dr. Selvaraj. mAB 3G8 (anti-CD16, blocking antibody), mAB 8c/6-39 (anti-
hIgG1), IgG2a from murine myeloma, and all FITC labeled secondary antibodies were 
purchased from Sigma-Aldrich (S. Louis, MO). Human IgG1 from myeloma cell culture 
were provided by Dr. A. Whitty from Biogen. FITC labeled mAB R19-15 (anti-mIgG2a), 
PE labeled mAB RR3-15 (anti- TCR Vβ 11), PE labeled mAB 145-2C11 (anti-CD3ε 
chain), and PE labeled mAB 53-6.7 (anti-CD8α (Ly-2)) were purchased from BD 
Biosciences Pharmingen (San Jose, CA). Purified mAB 5H10 (CD8 blocking antibody) 
was purchased from Caltag (Burlingame, CA). 
 
Peptide 
The nonamer peptides NP68 (ASNENMDAM) (agonist), P4Q (ASNQNMDAM) 
(partial agonist), P7E (ASNENMEAM) (antagonist), P8T (ASNENMDTM) and HIV gag 
(SQVTNPANI) (null) were custom synthesized and purified by RP-HPLC. 
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MHC Monomers and Tetramers 
 Biotinylated H-2Db monomers and tetramers incorporated with different peptide 
were provided by NIH Tetramer Facility (Bethesda, MD). 
 
Other Materials 
Carboxylated-modified microspheres, diameter 7.75 μm, and fluorescein 
microbeads standards were purchased from Bangs Laboratories (Fishers, IN). 
Carbodiimide kit for carboxylated-modified beads was obtained from Polysciences 
(Warrington, PA). Streptavidin, biotin-X-NHS kit, PP2, genistein, PD98059, BAPTA-
AM, latrunculin A, wortmannin were obtained from Calbiochem (La Jolla, CA). 
Sephadex G-200 was purchased from Pharmacia (Piscataway, NJ). Gel filtration column, 
gel filtration standard and fraction collector were obtained from Biorad (Hercules, CA). 
dimethylformamide was purchased from Pierce Biotechnology (Rockford, IL). Essential 
IgG free BSA, boric acid, phosphatidyl-inositol specific phospholipase C (PIPLC), 
tunicamycin, cytochalasin D, colchicine, methyl-β-cyclodextrin, and α-cyclodextrin were 
purchased from Sigma-Aldrich (S. Louis, MO).  
 
Cell Culture 
General Culture of CHO Cells 
CHO cells were cultured in RPMI with 10% FBS, 2mM L-glutamine, 1mM 
sodium pyruvate and 1% Penicillin/streptomycin according to standard practices. 
CD16aTM and B7-1-CD59 transfectant cell lines were supplemented with 400 μg/ml G-
418, while CD16aGPI, CD16bNA2 transfectant cell lines were supplemented with 400 
μg/ml hygromycin B as the selection agent.  
 
Naïve T cell Purification and T cell Activation 
F5 Transgenic T cells were purified from spleenocytes using murine T cell CD8 
subset column kit (R&D Systems Inc., Minneapolis, MN). A portion of the naïve F5 T 
cells were than activated in vitro with macrophage which were retrieved from Tap-/- 
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mouse and loaded with specific peptide. The ratio of naïve T cells to macrophages used 
was in the range 1.5-2.0. Both naïve and activated cells were cultured in complete RPMI 
media supplemented with 10% FBS, 5 x 10-5 M mercaptoethanol and 100U/ml IL-2. 
 
Covalently Couple 214.1 to Microspheres 
After washing by 2 x 1 ml carbonate buffer, 0.5 ml of 2.5% suspension of 
carboxylated microparticles were resuspended phosphate buffer (pH4.5) and washed 
three times in phosphate buffer. Pellet was resuspended in 0.02 M phosphate buffer, pH 
4.5. To the redispersed pellet, carbodiimide solution was added dropwise to reach a 
concentration of 4% and mixed for 3-4 hours at room temperature. Then the microspheres 
were washed 3 times in phosphate buffer to get rid of unreacted carbodiimide. Next, 200 
– 400 μg of capture antibody 214.1 was added to microspheres and incubated for 
overnight at room temperature with mixing. Microparticles were collected and 
supernatant was tested by BCA to estimate the efficiency of coupling. The pellet was 
resuspended in 0.2 M borate buffer and 50μl of 0.1 M methanolamine was added and 
mixed gently for 30 minutes at room temperature to block unreacted sites on the 
microparticles. Microspheres were then collected again and resuspended in 1 ml of 10 
mg/ml BSA solution and mixed gently for 30 minutes at room temperature. Repeat the 
last step once, but shorten the mixing time to 5 minutes. Finally microspheres were 
collected and stored in PBS with 1% BSA at 4°C until use. 
 
Chromium Chloride Coupling of IgG to RBCs 
Human IgG and mouse IgG2a were covalently coupled to the membranes of 
RBCs by means of a chromium chloride (CrCl3) method previously described [118]. 1% 
CrCl3 solution was prepared, properly aged at pH 5, and diluted in 20 mM acetate-
buffered saline, pH 5.5, at varies ratio (ranging from 1:100 to 1:800). Fresh red blood 
cells were washed 5X in saline and resuspended to 2% hct. IgG was added to each 250 ml 
sample and mixed. An equal volume of diluted CrCl3 solution was added dropwise with 
constant agitation. After 5 minutes the reaction was stopped by addition of 0.5 ml 
PBS/1% IgG-free BSA. Cells were subsequently washed and stored in EAS45 buffer. 1 
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ml aliquots from each sample were examined under light microscopy for aggregation. 
Samples were assayed for coating density and uniformity by flow cytometry. Appropriate 
ratios of protein to CrCl3 were determined empirically in a grid-design assay. While 
increasing levels of CrCl3 consistently increased the coating levels, this also increased 
the degree of cell aggregation. Increasing amounts of protein decreased aggregation, but 
did not necessarily increase the coating densities. In fact, excessive amounts of protein 
quenched the CrCl3 reaction completely. 
 
Biotinylation of RBC 
Human red blood cells were purified from fresh human blood and kept in EAS45 
for future use. Human RBCs were washed five times with PBS before biotinylation. 
Biotin-X-NHS was added to 10% RBC suspension at pH 9.0. After 30 minutes 
incubation at room temperature, the RBCs were washed five times by centrifugation with 
BSA/PBS (PBS containing 2 mg/ml BSA). Next, streptavidin (SA) was added to a 10% 
suspension of biotinylated-RBC (b-RBC) and, after 30 minutes incubation at room 
temperature, non-bound SA was removed by centrifugation. Then SA-b-RBCs were 
incubated with biotinylated monomeric pMHC for 1 hour at room temperature. Resulted 
RBCs were washed three times in PBS and stored in EAS45 buffer. 
 
Site Density Determination 
Site densities of proteins on red blood cells (IgG or pMHC), T cell (TCR, CD3 
and CD8) and polystyrene microspheres (solubilized CD16 captured by 214.1 covalently 
coupled to microspheres) were determined by quantitative direct fluorescent 
immunoassay (QIFI) [119-121] using monoclonal antibody against those proteins. 
Samples were prepared for flow cytometry using the usual flow cytometry staining 
protocol. FITC or PE (depend on mAB used) microbeads standards were tested under the 
same instrument setting as other samples. The mean fluorescence intensities for each 
fraction of the standard as well as the sample were acquired. The fluorescence intensity 
standard curve was plotted and total protein number per cell was calculated from the 
standard curve with protein/fluorophore ratio of the antibody provided by manufacture. 
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Finally, site density was calculated by dividing total protein number per cell by surface 
area of a cell. 
 
Micropipette Binding-frequency Assay 
Two-dimensional kinetic rates of cells-expressing receptor interacting with RBC 
coated-ligand were measured by micropipette method developed in our lab [118]. Briefly, 
a microchamber filled with 3 ml of buffer plus 1% BSA, 5mM EDTA, 0.04% sodium 
azide was mounted on microscope (Axiovert 100, Oberkochan, Germany) every time 
prior to experiment. Following introduction of 1 × 103 receptor-expressing cells and 1 × 
104 ligand-coated RBC to the chamber, a single receptor-expressing cell and a single red 
blood cell were respectively aspirated by two apposing micropipettes and aligned via 
micromanipulation. The red blood cell pipette was mounted to a computer-driven piezo 
translator, which moves the two cells into contact for a pre-determined area and duration. 
Upon the pipette retraction, the two cells either were immediately separated (i.e. no 
adhesion, scored 0) or remained bound with the red blood cell being elongated for a short 
time before being detached by force (i.e. adhesion, scored 1). This adhesion test cycle 
was then repeated on several pairs of cells for fifty times each to obtain an estimate mean 
adhesion probability for different contact duration which varies from 0.25 s to 16s. 
 
Size Exclusion Chromatography 
Monomeric and multimeric human IgG1 ligands were separated by gel filtration. 
7.5 g Sephadex G-200 (Pharmacia, Piscataway, NJ) was swelled in 200 ml PBS/EDTA 
(containing 5 mM EDTA, pH=7.4) at 90°C for 5 hr and then cooled at 4°C overnight. 
The supernatant was decanted and the gel was resuspended in 150 ml PBS/EDTA and 
poured into a column (1.7 cm in diameter, 150 ml in volume). Column was rinsed with 
300 ml PBS/EDTA between each run. After adding 5-20 mg IgG in 2 ml PBS/EDTA, the 
column was connected to a one-liter reservoir of PBS/EDTA. Setting the flow rate at 0.75 
ml/min, the effluent was collected sequentially in fractions of 1.5 ml each. The optical 
density (OD) at 280 nm was measured to monitor the protein concentration in each 
fraction. Gel filtration standard which contains 2.5 mg thyroglobulin, 2.5 mg bovine 
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gamma globulin, 2.5 mg chicken ovalbumin, 1.25 mg equine myoglobin, and 0.25 mg 
viamin B12 was loaded separately from the sample and the same procedure was 
performed. Optical density value for each fraction was plotted against the fraction 
number for both the gel filtration standard and sample. Fractions correspond to 
monomeric IgG were identified and sample was collected from these fractions for later 
use.  
 
Real Time Flow Cytometry 
Association experiment 
Five million cells (particles) were washed three times in 5 ml FACS buffer 
(RPMI, 1% IgG free BSA, 0.02% sodium azide). Resuspended cells in a FACS tube at a 
final concentration of 2.5 million/ml and mount the tube on the sample inlet valve. 
Started the timer when mixed the IgG with cells and take fluorescence histogram at 
different time point. The earliest time point can be at 10 second after sample mixing. The 
experiment will last for 12 minutes. Total 15 histograms were obtained from single test.  
 
Dissociation experiment 
The mixture left from association experiment was incubated for another 20 
minutes and centrifuge to pallet. The supernatant was decanted and pallet was vortexed in 
residue medium and ready for dissociation experiment. 2 ml plain medium was added to 
disperse cell particles while started the timer. The earliest time point can be at 10 second 
after plain medium was added. The experiment will last for 12 minutes. Total 15 
histograms were obtained from single test. 
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CHAPTER V 
MEASURING LIGAND-BINDING PROPERTIES OF FCγ 
RECEPTOR III  
IN REAL-TIME FLOW CYTOMETRY 
 
Introduction 
FcγRIII interacting with IgG has lower affinity and faster kinetics compared to 
antibody/antigen reaction. Several groups have studied the affinity and kinetics of 
different FcγRIII isoforms using different methods. Below is a summary of kinetics and 
affinities for different CD16 interacting with different IgG using four different assays, 
surface plasmon resonance (SPR, 3D), competitive inhibition assay (CI, 3D), 
micropipette (MP, 3D), and fluorescent recovery after photobleach method (FRAP, 2D). 
 
Table 5-1. Kinetics and affinity of 2D and 3D measurement for CD16 molecules 
             Parameter               
 
 Molecular                 
 System 







e-sCD16A – hIgG SPR 0.00471 0.00651 1.39 [122] 
e-sCD16A – hIgG1 SPR 0.00574 0.00818 1.41 [122] 
e-sCD16A – rIgG SPR 0.0186 0.01762 0.934 [122] 
p-sCD16BNA2 – 
hIgG1(aglycosylation) SPR 0.98 0.54 0.556±0.04 [123] 
p-sCD16BNA2 – 
hIgG1(aglycosylation) SPR 0.00193±0.0002 0.00210±0.0003 1.1±0.2 [124] 
e-sCD16BNA2 – hIgG1 SPR 0.00098±0.0003 0.00113±0.0003 1.3±0.6 [124] 
CD16ATM – hIgG CI – – 0.25 [25] 
CD16ATM – rIgG CI – – 0.93 [25] 
CD16ATM – mIgG2a CI – – 0.41 [25] 
CD16AGPI – hIgG CI – – 2.1 [25] 
CD16AGPI – rIgG CI – – 6.3 [25] 
CD16AGPI – mIgG2a CI – – 0.11 [25] 
CD16BNA1 – hIgG CI – – 0.032 [25] 
CD16BNA1 – rIgG CI – – 0.033 [25] 
CD16BNA2 – hIgG CI – – 0.019 [25] 
CD16BNA2 – rIgG CI – – 0.028 [25] 
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            Table 5-1 continued 
                      Parameter 







CD16ATM – hIgG MP 0.34 0.25 0.74 [25] 
CD16ATM – rIgG MP 0.24 0.58 2.4 [25] 
CD16ATM – mIgG2a MP 0.31 2.4 7.6 [25] 
CD16AGPI – hIgG MP 0.42 0.77 1.8 [25] 
CD16AGPI – rIgG MP 0.17 0.70 4.1 [25] 
CD16AGPI – mIgG2a MP 0.54 0.59 1.1 [25] 
CD16BNA2 – hIgG1 MP 0.64 0.24 0.38 [125] 




 (μm2)  









From the table above, one can see several discrepancies in the existing data. First, 
there is a thousand fold difference on dissociation rate constant between four methods, 
provided the units are the same even in different 2D and 3D measurements. The half-
lives acquired from micropipette are a few seconds, while SPR and FRAP measurement 
tends to get slower dissociation rate constant. Secondly, one can notice that due to the 
nature of a different method, the affinity and association rate constant acquired from three 
methods have different units. Thirdly, there is also a discrepancy within the same method 
SPR. For the same molecular pair sCD16BNA2-hIgG1, two groups obtained two 
dissociation rate constants, that differed a thousand fold, regardless the similar 
dissociation constant they obtained.  
One may also notice that two different sCD16BNA2 were compared in SPR 
experiments. One was synthesized by prokaryotic cell (p-sCD16BNA2), which was 
glycosylated, and another was synthesized by eucaryotic cell, which was aglycosylated. 
More consistent comparison of dissociation constant is among micropipette 
measurement, competitive inhibition assay and fluorescent recovery after photobleach 
method because all these three assays used CHO cell expressed CD16 molecules. 
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Therefore, developing a new 3D method that measures both affinity and kinetics and uses 
receptors reside in their native enviroment, cell membrane, is necessary. 
This aim was designed to develop a real-time flow cytometry method that 
satisfying above requirements. Two protocols were developed, association and 
dissociation, and their application on CD16aTM, CD16bNA2 were compared along. In this 




1. Size exclusion chromatography was used to separate monomeric IgG from aggregated 
IgG. 
To ensure monomeric ligand binding, size exclusion chromatography was used to 
separate monomeric hIgG1 from aggregated IgG. A mixture of five molecular weight 
markers, ranging from 1.35 to 670 kD, was used as a calibration standard for size 
exclusion columns. The mixture includes vitamin B12 and myoglobin, which are visible 
when eluting from glass and can be used to ensure that the column is properly packed and 
the sample is eluting evenly. Elution was collected at 1.5ml per fraction. The optical 
density (OD) at 280 nm was measured to monitor the protein concentration in each 
fraction. Sample was loaded separately from standard and optical density value for each 
fraction was plotted against the fraction number for both the gel filtration standard and 
sample. Fractions correspond to monomeric IgG were identified and sample was 
























Figure 5-1. Size exclusion chromatography of standard and hIgG1. Arrows indicate 
molecular weight for 5 components of the standard, thyroglobulin 670 KD, bovine 
gamma-globulin 158 KD, chichen ovalbumin 44 KD, equine myoglobin 17 KD, vatamin 
B12 1.3KD.  
 
2. Real-time flowy cytometry: association experiment 
Association experiment was designed to examine CHO CD16aTM and CHO 
CD16bNA2 interaction with hIgG1 in real-time. During experiment, 2.5 million CD16 
expressing cells were mixed with FITC-labeled hIgG1 for a designated concentration and 
meanwhile timer was started to record 0 time point. The mixture was immediately 
inserted to sample inlet valve of the flow cytometry and a histogram was taken every 15 
second during the first 2 minutes, then every 30 seconds for the next 2 minutes and at a 
larger interval as indicated on the figure till 16 minutes. At lease 15 histograms were 
acquired for each interaction course and several different ligand concentrations were tried 
for each CD16 interaction with hIgG1. Because of the low affinity of CD16 to hIgG1, 
high concentration of ligand is required to saturate the receptor. Therefore, background 
control is needed for each ligand concentration that has been tried. In this case, CHO 
cells tranfected with CD59 molecule was used. CD59 is known not to interact with hIgG1 
and this tranfection cell line is better than plain CHO cell in keeping the system 
consistent as all other cells tested are tranfected with different CD16s. Figure 5-2 show 
mean FI increases with increasing interaction time and finally reaches equilibrium when 
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CHO CD16aTM interaction with hIgG1. Total of 4 different ligand concentrations were 
tested, open symbols denote mean FI of background controls and solid symbols denote 
total mean FI of a sample. Noted that for higher ligand concentration, mean FI of a 
background is higher than mean FI of a total binding for a low ligand concentration, 

























Figure 5-2. Mean fluorescent intensity (FI) vs interaction time curve for CHO CD16aTM 
interacting with hIgG1 at 0°C, association phase. Open symbols are background. Solid 
symbols are total binding.  
 
3. Real-time flow cytometry: dissociation experiment 
The dissociation experiment was design to monitoring the dissociation of hIgG1 
from CD16 after their interaction reaches equilibrium. Therefore, in the experiment, half 
of the sample was used in the association experiment phase; the remaining half was 
allowed to incubate for another 20 minutes and then centrifuge to pellet. The supernatant 
was decanted and pallet was vortexed in residue medium and ready for dissociation 
experiment. 2 ml of plain media was added to already dispersed cells while timer was 
started. The mixture was immediately inserted to sample inlet valve of the flow 
cytometry and again a histogram was taken every 15 second during the first 2 minutes, 
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then every 30 seconds for the next 2 minutes and at a larger interval as indicated on the 
figure till 16 minutes. At lease 15 histograms were acquired for each interaction course 
and several different ligand concentrations were tried for each CD16 interaction with 
hIgG1 and same thing for background control. Noted that during dissociation, there is a 
fast dissociation phase before 4 minutes and a slower dissociation phase after 4 minutes. 
This could results from rebinding of the ligand to receptor and is taken into consideration 























Figure 5-3. Mean fluorescent intensity (FI) vs interaction time curve for CHO CD16aTM 
interacting with hIgG1 at 0°C, dissociation phase. Open symbols are background. Solid 
symbols are total binding. 
 
4. Models for data fitting. 
The association reaction can be modeled as monovalent receptor-ligand 
interaction where R, L and C are the concentration of free receptor, available ligand and 
receptor/ligand complex,  
      kf 
Eqn. 4-1R + L            C  
       kr 
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rf −=  Eqn. 4-2 
For the case of no ligand depletion and no change in total receptor concentration (RT = 




rTf −−= 0][  Eqn. 4-3 









rf +−−+++−=  
Eqn. 4-4 
where L0 is the initial ligand concentration and RT  is total receptor concentration. 




rnfn −=  Eqn. 4-5 
where B is the amount of non-specifically-bound ligand. The terms kfnL and krnB describe 
the non-specific cell surface association and dissociation events. The corresponding rate 
constants characterizing non-specific ligand interaction with the cell surface are kfn and 
krn. Solve equation 4-5 and assuming L is large compared to B, we get 
)1( tkfn rneLkB
−−=  Eqn. 4-6 
after fitting the background, it can be subtracted from total binding of each experiment. 
Figure 5-4a shows an example of the background fitting using equation 4-6 and a curve 
fitting using equation 4-4 for CHO CD16bNA2 interacting with hIgG1 at 0°C. The models 
fit both background and data well. Fitting reviews an initial fast increase phase and an 
equilibrium phase after 100 second.  CHO CD16aTM interaction with hIgG1 was similarly 






















Figure 5-4a. Curving fitting of association experiment of CHO CD16bNA2 interacting 
with hIgG1 at 0°C. 
 
 
Table 5-2. Kinetic rates and equilibrium dissociation constant of CD16 expressing on 
CHO cell binding to HigG1 at 0oC. 
Receptor kon (M-1s-1) koff (s-1) Kd (M) 
CD16aTM (1.81 ± 0.34) × 104 0.0038 ± 0.0005 (2.09 ± 0.30) × 10-7 
CD16bNA2 (2.55 ± 0.47) × 103 0.0245 ± 0.0014 (8.72 ± 0.21) × 10-6 
 Besides fitting association experiment, dissociation experiment was also fitted by 
modeling dissociation with following reaction scheme when association can be neglected 
during the initial phase of dissociation.  
      
R + L            C  
      kr
Eqn. 4-7




r−=  Eqn. 4-8
Equation 4-8 can be solved to give a general solution: 
Eqn. 4-9tkreCtC −= 0)(  
and above formula can be transferred to a linear equation: 
Eqn. 4-10ln(C/C0) = -kr t 
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When applied equation 4-6 to fit background in dissociation experiment of CHO 
CD16bNA2 interaction with hIgG1 and equation 4-10 to fit data, both models give a nice 
fit. However, the resulted dissociation rate constant is smaller than the one acquired from 
fitting association experiment, 0.0040 s-1 compared to 0.0245 s-1. It is possible that the 
























Figure 5-4b. Curving fitting of dissociation experiment of CHO CD16bNA2 interacting 
with hIgG1 at 0°C. 
 
5. Temperature effect on CHO CD16aTM binding to hIgG1. 
 Temperature is an important factor that affect affinity and kinetics of receptor – 
ligand binding. We are here to show that real-time flow cytometry is capable of 
measuring affinity and kinetics under different temperature. CHO CD16aTM was used as 
a model system and its interaction with hIgG1 under 4 different temperatures was 
investigated. A homemade water reservoir with constant temperature was used to 
incubate the reaction tube throughout experiment. The parameters were extrapolated from 
fitting association experiments and listed in table 2. This experiment reveals differences 
in binding parameter under different reaction temperatures. Especially for dissociation 
constant, it increases with increasing temperature as shown in figure 5-5. 
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 Table 5-3. Kinetic rates and equilibrium dissociation constant of CD16aTM expressing on 
CHO cell binding to HigG1 at different temperature. 
Temperature kon (M-1s-1) koff (s-1) Kd (M) 
0 oC (1.81 ± 0.34) × 104 0.0038 ± 0.0005 (2.09 ± 0.30) × 10-7 
15 oC (2.88 ± 0.44) × 104 0.0136 ± 0.0024 (4.71 ± 1.10) × 10-7 
20 oC (3.90 ± 0.55) × 103 0.0514 ± 0.0019 (1.32 ± 0.20) × 10-5 



















Figure 5-5. Relation between dissociation constant and temperature.  
 
Discussion 
 In this aim, a real-time flow cytometry protocol was developed to measure 
binding affinity and kinetics of low affinity FcγR, CD16. This method was applied to 
CHO CD16aTM and CHO CD16bNA2. The resulted parameters were well within the range 
of previous reported value [25]. Both the association experiment and dissociation 
experiment were modeled and the results show that dissociation experiment tends to yield 
a slower kr compared to kr that is yield from association. This could be that in 
dissociation experiment, the mean FI dropped from several hundreds to several tens of 
reading within first 15 second. Part of this dropping is resulted from non-specific binding 
that washed away by fresh media, but part of this dropping is due to fast dissociation 
phase. On the other hand, association well captures this fast interaction phase. The data 
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showed that there is clearly a fast association phase followed by equilibrium binding 
(Figure 5-4a).  
 An important binding property reveal by this experiment is the unusual relation 
between dissociation constant and temperature (Figure 5-5). It was first noted by 
Maenaka et al. that unlike FcγRIIa or FcγRIIb, FcγRIIIb exihibite increased Gibbes Free 
Energy (Figure 5-6, third panel), ΔG°, when the temperature increased [123]. ΔG° can be 
calculated from the Kd; ΔG°  = R × T × ln(Kd/C), where R is 1.987 × 10-3 kcal•mol-1K-1; 
Kd is expressed as mol•L-1; and C is 1 mol•L-1 (therefore making Kd/C dimensionless, as 
required). Our data show a similar trend if converted Kd to ΔG° following above 
equation. The reason for this difference in free energy existing among FcγRs is not 
known and it is thought to relate to structure differences among FcγRs.  
 
Figure 5-6. Gibbes free energy changes in relation with increased temperature for several 




QUANTIFYING THE EFFECTS OF MEMBRANE ANCHOR AND 
GLYCOSYLATION OF FCγ RECEPTOR III  




In this study, we applied three different methods to solubilize CD16 (sCD16), 
which gave three different anchor lengths: 
1, CD16 expressing-cell lysate (lysate), which results in soluble CD16 with full 
length in anchor, be it transmembrane or GPI (Figure 6-1a). 
2, Phosphatidylinositol-specific phospholipase C (PIPLC) treatment, which 
truncates diacyleglacerol from the GPI anchor to release the CD16 (figure 6-1b), 
resulting in a shorter anchor attached to the extracellular domain (figure 6-1a). 
3, CD16 spontaneously shed from cell membrane (shedding), which preserves the 
extracellular portion of the molecule but have no anchor at all (figure 6-1a). 
CD16aTM, CD16aGPI and CD16bNA2 were solubilized according to the above three 
methods. The resulting soluble CD16s were captured by a mAb that covalently attached 
to microspheres. Kinetics and affinities of these CD16s interacting with hIgG1 and 
mouse IgG2a were measured. Not only do the results support our previous findings, but 
they also demonstrate that a conformational change on receptor anchor can affect ligand 
binding as well. These effects can be inversed upon using another ligand.  
We also tested how glycosylation of the receptor affect ligand binding. 
Tunicamycin, a widely used N-glycosylation inhibitor, was added to culture medium to 
generate aglycosylated CHO CD16 isoforms. Glycosylation effect was also tested on 
soluble CD16, CD16aIg chimera (CD16aIg), by adding tunicamycin to CD16aIg 
secreting CHO cell culture. The resulting cell surface CD16s and CD16Ig were tested 
using micropipette adhesion assay and the affinities so acquired were compared with 













1. Release of membrane CD16s (mCD16s) by three solubilization methods and their 
coating on microspheres. 
The cell expressing CD16 molecules were released from membrane by lysing the 
cell, using PIPLC to cleavage diacyleglacerol off a GPI anchor (PIPLC) or by 
spontaneous shedding in a serum free media (shed). After PIPLC treatment or shedding, 
cells were stained for their surface expression of CD16 and the surpernatant was used to 
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incubate 214.1 coated microspheres. Figure 6-2 shows the decrease expression of surface 
CD16s after these treatments and the capture of sCD16 by 214.1 on microspheres.   
   
 
Figure 6-2a. FACS comparison of CHO CD16aGPI before and after PIPLC. Thin line, 





Figure 6-2b. FACS comparison of CHO CD16aGPI before and after shedding. Thin line, 





Figure 6-2c. FACS of solubilized CD16 captured by 214.1. Thin line, background; red 
area, CD16aGPI shedding captured by 214.1 beads; blue area, CD16aGPI PIPLC captured 
by 214.1 beads. 
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2. Microsphere-reconstituted CD16bs (mrCD16s) bind specifically to RBC-bound IgG 
Binding specificity of mrCD16s coated on microspheres and IgG coated on RBC 
was tested using micropipette adhesion frequency assay (figure 6-3). Micospheres coated 
with BSA showed minimum binding to RBC-bound IgG. RBCs underwent the same 
procedure without adding IgG also showed minimum binding to mrCD16s. mrCD16aTM 
show an average of 54% of adhesion probability with standard deviation of 13% 
estimated from 5 pairs of cells and beads tested 100 times each. Incubation of mrCD16s-
coated microspheres with a function-blocking anti-CD16 monoclonal antibody 




















Figure 6-3. Specificity test of mrCD16 interacts with RBC.  
 
3. Both mCD16aGPI and sCD16aGPI (lysate) bind hIgG with a higher affinity than 
CD16aTM 
CD16aTM and CD16aGPI lysates were generated and captured by 214.1 coated 
microspheres.  Kinetics and affinity of these CD16s interacting with hIgG1 coated on 
RBC were measured by micropipette adhesion frequency assay.  In this experiment, 
seven contact time points were chosen ranging from as short as 0.5 s to as long as 16 s.  5 
pairs of cells were tested for each time point and 100 adhesion repeats were done for each 
cell pair to calculate adhesion frequency. Resulted adhesion frequency is total adhesion 
frequency (Pt), which has to be normalized into specific adhesion frequency (Pa) by 
removing nonspecific adhesion frequency (Pn) using Eqs. (5-1), [126].  
Pa = (Pt - Pn)/(1-Pn)    (5-1) 
resulted Pa was then fitted by Eqs. (2) [118] to retrieve affinity and kinetics information. 
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Pa = 1 - exp {-mrmlηAcKa° [1 – exp { - koff °t} ]   (5-2) 
These kinetics and affinities were plotted in comparison with kinetics and affinity of 
mCD16 interacting with hIgG [25]. sCD16aGPI from lysate binds hIgG with a higher 
affinity than sCD16aTM from lysate, just like the previous results with cell surface 
CD16aGPI and CD16aTM (figure 6-3a). Both sCD16aTM and sCD16aGPI from lysate have 
higher affinities than their respective membrane counterparts. This is likely because 
microspheres have a smoother surface compared to the CHO cells membrane, which 
results in a different fractional true contact area, η. Kinetics measurement from 
micropipette adhesion assay also reveals that despite the difference in fractional true 
contact area, the reverse rate constants (off-rate, kr) of these four CD16s interacting with 
their ligand are quite comparable (figure 6-4b). Then the differences in affinity between 
CD16aGPI and CD16aTM come from forward rate constant (on-rate, kf) (figure 6-4c).  
 
Figure 6-4a. Affinity comparison between CD16 lysate and CHO CD16. η = fractional 




Figure 6-4b. Reverse rate constant comparison between CD16 lysate and CHO CD16.  
 
 
Figure 6-4 c. Forward rate constant comparison between CD16 lysate and CHO CD16. η 
= fractional true contact area. 
 
4. Anchoring length of a molecule affects ligand-binding affinity. 
Lysing the cells, PIPLC enzymatic cleavage and shedding were used to solubilize 
CD16a-GPI and CD16bNA2. Resulted molecules differ from their anchor lengths: lysing 
the cells allows the molecule to retain it’s original GPI anchor, PIPLC cleavages part of 
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the GPI anchor; spontaneous shedding is the action of metalloproteinases bound to the 
cell membrane, resulting in molecules with no GPI anchor. Micropipette adhesion assay 
was applied to measure affinity of these molecules at a contact time long enough for the 
interaction to reach equilibrium. Previous kinetics measurements of mCD16 and sCD16 
revealed that interactions between CD16 and hIgG1 had reach equilibrium at 8 second 
contact regardless of the ligands used.  Adhesion frequencies were measured at 8 second 
contact time and normalized using equation 5-1. Affinities were then estimated from 
equation 5-3, which is a transformation of equation 5-2 when the interaction reaches 
equilibrium, contact time t approaching infinity.  
AcKa° =  - Ln (1 - Pa) / mrml   (5-3)  
Progressive shorterning of the anchor length of CD16aGPI resulted in a progressive 
increase in its affinity for hIgG1 (figure 6-5 middle panel). The same result was seen with 
CD16bNA2, which is also a GPI anchored molecule (Figure 6-5 left panel). Further 
confirmation was obtained using CD16aTM, the anchor length of which can be changed 
by using cell lysate (full transmembrane anchor) and by shedding (no membrane anchor). 
The polypeptide transmembrane anchor resists PIPLC cleavage so only two anchor 
lengths were obtained. Affinity measurements show that CD16aTM-lysate has a much 
higher affinity then CD16aTM-shedding (Figure 6-5 left panel). Since the only difference 
between CD16aTM and CD16aGPI is in their anchor, these two molecules should have 
identical structure once they both became soluble by shedding and their affinity to hIgG1 
should be the same. Our measurements show CD16aTM-shedding and CD16aGPI-shedding 
have respective affinity of 0.17 ± 0.10 × 10-6 μm4 and 0.38 ± 0.10 × 10-6 μm4, which are 
not statistically significantly different (p = 0.0925, Student t-test). Student’s t-test has 
been used to compare two means at a time and the p values were indicated on the figure 
for every pair of test. All p values are reasonably small, confirming that, for all three 
CD16 molecules (CD16aTM, CD16aGPI, and CD16aNA2), the lysate form has a 
significantly higher affinity for hIgG1 than the PIPLC cleavaged (wherever available), 




Figure 6-5. Affinity comparison of CD16 shedding, lysate and PIPLC binding to human 
IgG1 at 8 seconds. 
 
5. The trend of anchoring effect on ligand binding was inversed when ligand was 
changed from hIgG1 to mouse IgG2a. 
Previously we found that membrane CD16aGPI binds to hIgG better than 
CD16aTM. However, when ligand was switched from hIgG to mouse IgG2a, CD16a-TM 
binds better than CD16aGPI (Chesla et al., 2000). In this study, ligand was switched from 
hIgG1 to mIgG2a and affinities were acquired as described in the preceding section. It is 
eveident that both CD16aTM-shedding and CD16aTM-lysate bind better than their 
CD16aGPI counterparts (Figure 6-6 left and middle panels), consistent with our previous 
results (Chesla et al., 2000). Interestingly, the correlation between CD16a anchor length 
and its affinity for ligand is inversed when ligand changed from hIgG1 to mIgG2a for all 
membrane isoforms of CD16 (CD16aTM, CD16aGPI, and CD16aNA2), such that the lysate 
form with the full anchor binds with the lowest affinity, the shedded form with no anchor 
binds with the highest affinity, and the PIPLC cleaved form (for CD16aGPI and CD16aNA2 
only) with part of the GPI anchor binds with intermediate affinity (figure 6-6). Again, 
Student’s t-test has been used to compare two means at a time and the p values were 
indicated on the figure for every pair of test. All p values are reasonably small, 
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confirming that, for all three CD16 molecules (CD16aTM, CD16aGPI, and CD16aNA2), the 
shedded form has a significantly higher affinity for mIgG2a than the PIPLC cleaved 
form, which in turn has a higher affinity for mIgG2a than the lysate form. 
 
 
Figure 6-6. Affinity comparison of CD16 shedding, lysate and PIPLC binding to mouse 
IgG2a at 8 seconds. 
 
6. Glycosylation of a receptor affects ligand binding properties. 
In order to investigate the effect of receptor glycosylation on ligand binding 
properties, we compared affinity and kinetics of CHO CD16 interacting with hIgG1 with 
aglycosylated CHO CD16. In this experiment, tunicamycin, a widely used N-
glycosylation inhibitor, was added to culture medium for 40 hr. This does not affect 
CD16 expression significantly as revealed by FACS (data not shown). All three CD16 
cell lines were cultured in the same way and resulted cells were washed and then put into 
test chamber. Affinities and kinetics were estimated as previously described. Figure 6-7 a 
and b show affinity and reverse rate constant of CD16 transfected CHO cells treated with 
tunicamycin in this study in comparison with previously published data on the same CHO 
cells without the treatment [25, 125]. All three CHO CD16s that are treated with 
tunicamycin exhibit higher affinity for hIgG1 then untreated controls.  In contrast to 
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affinity, tunicamycin does not have dramatic effect on kr. Reverse rate constant for all 
three CD16 is about 1 s-1. 
 
 
Figure 6-7a. Affinity comparison of CHO CD16 treated or untreated with tunicamycin. 
 
 





Our goal was to determine how the membrane anchor and glycosylation of CD16 
affect its ligand binding. Previous studies have shown that CHO cell CD16a
GPI
 had a 3-
fold higher affinity for hIgG than CHO cell CD16a
TM




TM are identical, which are also identical to the CD16a 
portion of the sCD16a-Ig chimera, these data suggest the GPI anchor as the likely cause 
for the affinity difference. This work tested this hypothesis by comparing CD16 with full 
anchor and with various truncations in the anchor. We showed such structural variations 
near the membrane anchor affect the global conformation of CD16, which propagates to 
the ligand binding site, thereby affecting ligand binding affinity (Fig. 5-5, 6). Our data 
also provide another example for long range propagation of conformational changes that 
result in differences in ligand binding affinity.  Similar examples have been demonstrated 
in integrins where such conformational changes are related to inside-out as well as 
outside-in signaling [127]. Yet another example is the bacterial FimH receptor for 
carbohydrates where structural variations distal to the binding site affect the mechanical 
properties of the interaction [128]. Apart from anchoring effect, we also show that 
glycosylation will dramatically inhibit ligand binding by 100 folds. Previously, Galon et 
al. have studied the affinity and kinetics of the interaction between human IgG1 and two 
soluble forms of CD16 (sCD16) corresponding to the 188 N-terminal amino acids of the 
extracellular region of the receptor using SPR, a glycosylated one made in eucaryotic 
cells (euc.sCD16) and an aglycosylated one (proc.sCD16) made in Escherichia coli.. 
Their results show that hIgG1 bound to immobilized euc.sCD16 with an affinity constant 
of 1.3 × 106 M-1 and the affinity constant of proc.sCD16 for human IgG1 was in the same 
range, 1.1 × 106 M-1 [124]. It is hard to believe that such a small difference in affinity 
between glycosylated and glycosylated CD16 would account for the huge difference 
observed in vivo study [22]. We also compared affinities between a glycosylated and an 
aglycosylated CD16aIg chimera binding to hIgG1. Aglycosylated CD16aIg chimera was 
obtained by culturing chimera secreting cells in medium supplemented with tunicamycin. 
Surprisingly, these two have similar affinity, ~ 5.37 × 10-6 μm4. Further investigation 
reveals that in the culture supernantant of CD16aIg chimera, a significant portion of 
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aglycosylated CD16aIg is present as shown in western blot (Fig 5-8). So, if the 
aglycosylated form of CD16 indeed has about 100 folds higher affinity for hIgG1 than 
the glycosylated form as show for cell expressed CD16s, then the significant portion of 
aglycosylated CD16aIg chimera present in tunicamycin negative culture medium could 
dominant the binding and it could be the reason that the affinities we measured of these 
two CD16aIg chimera are similar. Separation of these two forms of CD16aIg chimera is 
underway using Lectin, which are capable of binding glycoproteins. Further investigation 
is needed to study the affinity on two purified populations to clarify this issue. 
 
Figure 6-8. Western blot of cell culture supernant with or with tunicamycin at reducing 
condition. Tuni – tunicamycin. 
 
In vivo, CD16 alleles have different affinities towards monomeric IgG and immune 
complex. This is an important regulator in selectively activating some cells but not all 
cells that express CD16. More importantly, same CD16 encoded by the same gene could 
undergo differential cell type-specific glycosylation as suggested by Edberg and Drescher 
[22, 23]. This 20 to 100 folds increase in affinity shown in current study could be an 
extreme case as tunicamycin inhibits all N-glycosylation. However, this broad range 
change in affinity could offer more subtleness in regulating cell activation. In human, 
monomeric IgG is about 20 mg/ml in plasma and this is not sufficient for low affinity 
CD16 to bind and trigger cell activation. However, cells that express higher affinity 
CD16 could be activated even at this IgG concentration. 
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CHAPTER VII 




Similar to the interactions of FcγRIII with IgG, TCR/pMHC interaction is also of 
low affinity and mediates weak adhesion. Their affinity and kinetics are important 
determinants of T cell antigen recognition. However, those measurements were not 
available until the merge of SPR. SPR measurements require that both receptor and 
ligand be purified and isolated from the cell membrane and one of them immobilized on 
the sensor chip while the other flowing in fluid phase. Recent experiments have shown 
that activated T cells react to pMHC better than naïve T cells. This difference could result 
from differential organization of TCRs on activated T cells and on naïve T cells. 
Micropipette adhesion frequency assay measures kinetics with receptors residing in their 
native environment, thereby allowing us to explore this difference.  
In this aim, T cells from two clones of transgenic TCR mice were tested, 2C and 
F5. Naïve and activated 2C T cells were provided by Dr. Jonathan Schneck of the Johns 
Hopkins University. Spleen of F5 transgenic mice were provided by Dr. Suryaprakash 
Sambhara of CDC. Naïve T cells from F5 transgenic mice were purified using negative 
selection methods and maintained in complete medium supplemented with IL-2 for 
subsequent use. Portion of these naïve cells were activated with macrophages harvested 
from Tap knockout mice at a ratio 1:2. Macrophages were preloaded with agonist peptide 
for one hour at room temperature and excess peptide was washed away before addition of 
T cells. Either naïve or activated T cells were tested in the micropipette experiments for 
adhesion with RBCs coated with pMHC. For testing of F5 T cells, RBCs were 
biotinylated and incubated with streptavidin. After wash, four different pMHC monomers 
(agonist, partial agonist, antagonist and null) the C termini of which were tagged with a 
biotin (provided by the NIH Tetramer Facility at Emory University) were added 
separately to the RBCs. For testing of 2C T cells, a goat anti-mouse secondary antibody 
was first immobilized onto RBC surface using chromium chloride method. Then, pMHC 
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dimer incorporated with cognate or noncognate peptpide was added to RBC separately. 
Site densities of pMHCs as well as TCR were quantified by flow cytometry.  
Using the above systems, we made the first in situ 2D affinity and kinetics 
measurement of TCR interacting with peptide-MHC. For the F5 TCR, eight sets of 
affinity and kinetics data were collected and compared, including TCR on both activated 
T cells and naïve T cells interacting with four different pMHC. For 2C TCR, four sets of 
affinity and kinetics data were collected and compared, including TCR on both activated 
T cells and naïve T cells interacting with either cognate or noncognate pMHC. Results 
show that TCR on activated T cell has a higher affinity for pMHC. Though they trigger 
different biological outcomes, agonist pMHC and antagonist pMHC exhibit similar 
affinity and kinetics for TCR under the conditions tested.  
 
Results 
1. T cells bind specifically and stably to pMHC coated RBC. 
Specificity of TCR binding to pMHC was tested using RBC coated with pMHC 
or irrelevant protein or uncoated RBC interacting with naïve T cells. As can be seen in 
figure 7-1a, agonist-pMHC coated RBC showed a 26% adhesion frequency. The other 
two kinds of RBC showed <1% adhesion frequency, suggesting that biotinylated RBC 
has a clean background in the micropipette adhesion assay. In order to eliminate potential 
interaction between LFA-1 expressed on T cell and ICAM-3 expressed on RBC, 5mM of 
EDTA was added to chamber buffer to see whether the adhesion frequency can be 
reduced. Results showed that T cell-RBC adhesion frequencies remained unchanged, 
confirming that the adhesion observed is not mediated by integrin and its ligand (Fig 6-
1b).  Nevertheless, EDTA was used in all the experiments presented in this Chapter to 
eliminate any potential divalent cation dependent interactions, including integrins, 
selectins, and cadherins. TCR has been known to rapidly internalize once in contact with 
ligand. To prevent TCR internalization, 0.04% sodium azide was added to the media in 
all the experiments presented in this Chapter, as it did not change the binding frequency 
as shown in figure 7-1b. The running frequency is plotted against the adhesion test cycle 
to test if the adhesion functionality changes during the time of assay. Results showed that 
the running frequency fluctuated initially due to small sample size, but then became 
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stabilized as the test cycles increased, indicating that TCR was not internalized by T cell 
















































Figure 7-1b. Adhesion frequency of naïve T cells interacting with agonist-MHC coated 

























Figure 7-1c. Running frequency of naïve T cells interact with agonist pMHC coated 
RBCs.  
 
2. Activated T cells show higher adhesion frequencies for pMHC than naïve T cells for 
the same TCR and pMHC densities. 
 Naive and activated T cells were tested for adhesion with different pMHC bearing 
RBCs. Three individual experiments were performed for each T cell and pMHC 
combination. At least 30 pairs of cells were tested in each experiment in order to 
complete a whole binding curve, which are exemplified in Figures 6-2a. Each point on 
the figure represents mean ± s.e.m. of adhesion frequency estimated using 5 pairs of cells. 
For each pair of cell, 50 adhesion cycles were tested and adhesion score, either 0 for non-
adhesion or 1 for adhesion, were recorded to calculate the adhesion frequency. Equation 
5-2 was used to fit the binding curved both for naïve and activated T cells. It assumes that 
the kinetic mechanism is second-order forward, first-order reverse, single-step 
bimolecular monomeric binding. Resulted affinity and kinetics for F5 T cells were 
plotted in figure 7-2b and c. The binding of both naïve and activated T cells to RBC 
coated with null pMHC was similar to background level. Therefore the affinity cannot be 
estimated.  By comparison, activated T cells have a higher affinity than naïve T cells for 
all other three pMHCs. A possible explanation maybe that TCR may be better organized, 
for example, forming dimmer, on activated than on naïve T cells. The results also show 
that partial agonist pMHC has a much lower affinity than agonist pMHC, which 
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correlated to their biological function, as partial agonist is not as potent as agonist in 
stimulating T cell activation. However, antagonist pMHC, which does not elicit T cell 
activation by itself and antagonize the agonist effect when both peptides are presented by 
antigen presenting cells (APC), has a comparable affinity for TCR on both naïve and 




























Figure 7-2a. Comparison between measured (points) and fitted (curves) adhesion 
frequencies between naïve F5 CTL and RBC coated without (background) or with MHC 
complexed with the indicated peptides. 
 





Figure 7-2c. Reverse rate constant comparison between naïve and activated T cells 
interacting with different pMHCs. 
  
Another important kinetic parameter estimated from fitting the adhesion 
frequency data in figure 7-2a is the dissociation rate constant, kr, which measures how 
fast a bond between a receptor and a ligand dissociates or the reciprocal lifetime of a 
bond. In the case of TCR/pMHC interaction, the dissociation rate constants measured in 
this study are faster than some other weak adhesion measured in micropipette, e.g. CD16 
(~ 0.5 s, [25, 118]). The results indicate that both naive and activated F5 T cell has 
comparable dissociation rate constants for all three pMHCs. This fast dissociation may 
allow TCR to quickly scan hundreds and thousands of pMHC presented on APC surface 
to find agonist pMHC to lunch an activation process. 
 
3. CD8 did not contribute to T cell adhesion with pMHC-coated RBC. 
We have shown that integrins do not participate in the measured adhesions of T 
cells, which depend on pMHC. However, it is still possible that TCR-pMHC interaction 
triggers the recruitment of other adhesion molecules that mediate the measured 
adhesions. CD8 also can interact with pMHC through a different epitope (figure 3-3). To 
assess the CD8 contribution to adhesion, we used two CD8 blocking antibodies, 53-6.7 
(BD Pharmingen, CA) and 5H10 (Caltag, CA) to blocking any CD8 mediate adhesion. 
The first antibody has been reported to inhibit the CD8 dependent tyrosine 
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phosphorylation events in CTL [129] and second antibody has been reported to block 
CD8. Results with F5 TCR indicated that adhesion frequencies between naïve T cells and 
agonist-pMHC coated RBCs remained unchanged when T cells were incubated with as 
high as 10ug/ml of these two antibodies, which was also present in the chamber media. In 
next Chapter, CD8 will be shown to participate in the strong adhesion observed in 
isotonic condition. Hypotonic condition seems to disrupt the association of CD8 to TCR 
through an unknown mechanism so that TCR-pMHC engagement could not upregulate 
CD8 dependent binding of pMHC. This CD8 related upregulation of adhesion is further 
studied in next result section. 
Besides CD8 blocking experiments, binding to null-pMHC was no higher than 
background level even at the highest possible pMHC coating density. The other three 
pMHCs all gave adhesion frequencies significantly higher than the background level. If 
the CD8 binding to pMHC was independent of TCR, it would have shown some signal 
when T cells were allowed to interact with null-pMHC-coated RBCs. However, the result 
shows that null-pMHC cannot elicit any adhesion, indicating that CD8/pMHC 
interaction, if any, is too weak to be detected by micropipette. Since the micropipette 
assay is sensitive enough to detect adhesion mediated by as low as a single receptor-
ligand bond and since no CD8/pMHC interaction can be detected at respective CD8 and 
pMHC densities as high as 400 and 800 μm-2, the affinity of CD8/pMHC binding must be 


















hypotonic 56% 44% 47%
no ab 5H10 53-6.7
 
Figure 7-3. Adhesion frequency between naïve T cell and agonist-MHC coated RBC at 8 
second contact in the presence or absence of two CD8 blocking antibodies. 
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 4. TCR blocking antibody affects binding to agonist and antagonist pMHC differently 
 In order to test the specificity of TCR/pMHC interaction and dissect the role of 
CD8 in TCR mediated adhesion, Fab of a TCR Vβ11 blocking antibody (RR3-15) was 
tested for its ability to block TCR/pMHC interaction using naïve F5 T cells. At 25μg/ml 
concentration, it completely blocked the TCR interactions with partial and antagonist 
pMHC. However, it only reduced the adhesion frequency mediated by TCR and agonist 
pMHC by 35%. Increasing the antibody concentration to 50μg/ml further reduced 
adhesion frequency by 78% (Fig. 6-4a). Both antibody concentrations were repeated for 
agonist pMHC and resulted binding curves were fitted together with the binding curve 
that no blocking antibody was added. Equation 5-2 was modified by taking into account 











Results show that at mAb concentrations of 25 and 50 μg/ml, respectively 86% and 92% 
of TCRs were effectively blocked (Fig 6-4b). The best-fit parameters resulted in a 2D 
effective affinity, AcKa = 34.8 × 10-6 μm4, reverse rate constant kr = 0.82 s-1, and the 3D 






















Figure 7-4a. Blockade by Fab of anti-TCR Vb11 mAb RR3-15 was more effective for 
binding of partial pMHC and antagonist pMHC than agonist pMHC.  
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Figure 7-4b. Global fits of adhesion frequency data of naïve T cells interacting with 
agonist pMHC without or with different concentrations of blocking mAb.  
 
5. Confirmation of key results using 2C TCR.  
Naive and activated T cells from another clone of transgenic TCR, 2C, were also 
tested for adhesion with cognate and noncognate pMHC bearing RBCs. Each T cell and 
pMHC combination was test once by using at least 30 pairs of cells in each experiment in 
order to complete a whole binding curve. Resulted affinity and kinetics were plotted in 
figure 7-5a and b, which show that activated T cells have a higher affinity than naïve T 
cells for both the cognate and noncognate pMHCs, confirming our observation with the 
F5 TCR. The results also show that noncognate pMHC, which does not elicit T cell 
activation by itself had a comparable affinity for TCR as cognate pMHC for both naïve 




Figure 7-5a. Affinity comparison between naïve and activated 2C T cells interacting with 




Figure 7-5b. Reverse rate constant comparison between naïve and activated 2C T cells 
interacting with cognate and noncognate pMHCs fitted using monomeric model. 
 
The TCR-pMHC dissociation rate constants, kr, are comparable for naïve and 
activated 2C T cells. However, noncognate pMHC had faster dissociation rate constants 
for TCR on both naive and activated T cells. Compared with previous F5 data, the kr 
value for cognate pMHC is in the same range of agonist pMHC and kr value for 




 We measured adhesion frequencies between TCR from naïve or activated mouse 
CTL and RBC coated with four pMHC known to elicit distinct activation states (Figs. 1E 
and 2). The measured dependence of adhesion frequency on contact duration as well as 
on densities of TCR and pMHC enabled reliable estimates of kinetic and affinity 
constants for the agonist, partial agonist, and antagonist pMHC (Figs. 2 and 3), which 
represent the first in situ 2D kinetic measurements of this kind. For both naïve and 
activated CTL, adhesion frequencies were reduced to the background level (< 0.02%) 
when the null peptide was used, suggesting their much lower affinities. Thus, the 
component of CD8-pMHC interaction that is independent of pMHC-TCR interaction and 
independent of the peptide could not be stronger than the interaction of TCR with null 
pMHC, which was undetectable event at CD8 and pMHC densities as high as 400 and 
800 μm-2. The agonist and antagonist pMHC had similar affinities for TCR, which were 
higher than that of partial agonist pMHC. The off-rate of partial agonist pMHC 
dissociating from TCR was faster than agonist pMHC, which was similar to antagonist 
pMHC. 
 The binding affinity of TCR from activated CTL showed trends similar to those 
from naïve CTL but shifted towards higher values relative to those from naïve CTL in 
two transgenic T cell clones, suggesting that activated T cells better organize their TCR 
on the cell surface for more effective binding. This is consistent with previous report that 
activated T cells have an enhanced ability to cross-link TCR. The off-rates of TCR from 
activated CTL appeared similar for agonist, partial agonist, and antagonist peptides. 
 Frequencies of adhesion between naïve CTL and RBC coated with agonist pMHC 
were comparable with those coated with antagonist pMHC and were only < 2-fold higher 
than those coated with partial agonist pMHC in the absence of anti-TCR blocking mAb 
RR3-15 (Fig. 4). However, in the presence of mAb RR3-15 the adhesion frequencies for 
partial agonist and antagonist pMHC were reduced to much greater extent than those for 
agonist pMHC, even when the mAb concentration used in the agonist pMHC experiment 
was twice of that used in the partial agonist and antagonist pMHC experiments (Fig. 5). 
This suggests that the detail interactions and structure in the contact surface between 
TCR and agonist pMHC might be different from those between TCR and partial agonist 
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and antagonist pMHC. This raises the question of whether there are other determinants of 
TCR discrimination in addition to kinetics and affinity. 
 The lack of TCR kinetic and affinity differences between agonist (or cognate) and 
antagonist (or noncognate) pMHC was quite surprising and puzzling, as differences have 
been found by other cell adhesion assays. One may question whether the assay and/or the 
experimental conditions are adequate. However, the micropipette adhesion frequency 
assay performed in hypotonic medium condition has been successfully used to measure 
the kinetics of ligand and antibody binding of Fcγ receptors, selectins, and integrins. The 
conditions include hypotonic media to swell the RBC to nearly spherical shape when 
captured by micropipette, addition of EDTA to inhibit divalent cation dependent adhesion 
pathways, and addition of sodium azide to inhibit energy dependent active processes. 
While these conditions suppress T cell signaling, they should not be any worse than the 
conditions used in the SPR experiments. In subsequent experiment (Chapter 7, below), 
we found that, under physiological conditions agonist pMHC, but not antagonis pMHC, 
induce a signaling dependent strong adhesion to T cell that includes a major contribution 
from CD8. To examine whether the difference in medium osmorality also impact 2D 
kinetic measurements of adhesion mediated by other receptor-ligand interactions, 
CD16aGPI on CHO cells, PSGL-1 on HL-60 cells, and LFA-1 on both K562 cells and 
naïve F5 T cells were tested with their respective ligands coated on RBC either in 
hypotonic medium or isotonic medium. No differences were observed in the adhesion 
frequency measured in hypotonic and isotonic medium using the same batch of cells 
(Figure 7-6). This suggested that the medium effect is specific for TCR, which is capable 
of converting weak adhesion into strong adhesion by signaling to recruit CD8. It is 
possible that TCR has a different membrane association property, for example association 
with lipid rafts, which is sensitive to hypotonic treatment. This is further investigated in 































Figure 7-6. Adhesion frequency comparison for CD16aGPI on CHO cells, PSGL-1 on HL-
60 cells, and LFA-1 on both K562 cells and naïve F5 T cells interacting with their 
respective ligands coated on RBC, hIgG1, P-selectin, ICAM-1. 
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CHAPTER VIII 
INVESTIGATING TCR-TRIGGERED SIGNALING-DEPENDENT 
RAPID TRANSITION TO CD8-MEDIATED STRONG ADHESION 
 
Introduction 
Upon engagement of pMHC, TCR recognizes different antigenic peptides 
incorporated in the MHC and generates distinct signals. Together with its coreceptor and 
other accessory molecules, they orchestrate different responses. Over the past several 
years, significant advances have been made in elucidating the molecular details of 
signaling cascades triggered by TCR engagement. Recent discovery of immunological 
synapse and application of different fluorescent microscopic technologies have brought 
us colorful and live pictures of what are happening on the T cell/APC contact. However, 
due to the insufficient temporal resolution of these techniques, events that happen in the 
first several seconds immediately after the T cell makes contact with an APC is still not 
well defined. We previously noticed that T cells develop strong adhesion for agonist 
pMHC coated RBC, which is different from the weak adhesion we saw in the affinity and 
kinetics measurements (see Chapter VI). In this Chapter, we continue to explore this 
transition from weak adhesion to strong adhesion. We took advantage of the micropipette 
adhesion assay, which allows us to measure adhesions developed within very brief 
contacts between a T cell and a pMHC decorated RBC. Results obtained under 
physiological conditions show that T cells develop aggravated adhesion for agonist-
pMHC on RBC but not for other pMHCs. We further show that, this change in adhesion 
mode happens around 0.75 second after TCR in contact with pMHC and can be 
completely blocked by anti-CD8 antibody. It can also be reduced by inhibiting protein 
tyrosine kinase (PTK) activation, disrupting membrane rafts, and dissolving actin 
cytoskeleton. Tetramer binding experiment showed that the same inhibitors that 
effectively blocked CD8 up regulated strong adhesion in micropipette experiment failed 
to block soluble tetramer binding in fluid phase.  
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Results 
1. Naïve T cell developed strong adhesion to RBC coated with agonist but not antagonist 
pMHC. 
 During TCR affinity and kinetics measurements, it was noticed that in rare cases, 
T cells developed very strong adhesions for agonist pMHC coated RBC, which were very 
different from the weak adhesions commonly seen in the assay. Instead of isolated point 
attachments that could be easily dissociated by a low aspiration pressure of few 
millimeters of water height, which is characteristic of the weak adhesion, the RBC 
formed a large continuous area of adhesion with the T cell that could not be separated by 
a much higher level of aspiration pressure. While such strong adhesions were rarely seen 
when the experiment was performed in hypotonic media, they occurred in every single 
test with every pair of cells tested when the chamber solution was changed to isotonic 
medium. In order to assess the strong adhesion more efficiently, a population assay, 
rosetting, was adapted. In short, naïve T cells were mixed with pMHC coated RBC at a 
ratio of 1:100 and the mixture was gently spin and cell pallet was incubated for indicated 
period of times. Then the fraction of T cells that formed rosettes with RBC and the 
distribution of rosette size (i.e., the number of RBC per T cell) were enumerated under a 
microscope by observing a total of one hundred T cells per condition per experiment. As 
shown in figure 8-1a, among the four pMHCs tested agonist pMHC has the highest 
percentage of rosette, partial agonist pMHC has a much lower percentage of rosettes, and 
no rosette was formed between T cells and other two pMHCs. These results are in sharp 
contrast to the data obtained in the preceding chapter but consistent with the expected 
ability for TCR to discriminate different types of antigen peptides. In both cases of 
agonist and partial agonist pMHC, the rosette percentage increased with increasing 
incubation time. Rosette percentage also increased with increasing pMHC site density, as 
expected from the law of mass action. At a coating site density of 250 sites/μm2, which is 
twelve times more than that used in figure 8-1a, almost all T cells form rosette even at the 
shortest incubation time allowed, 2 minute (figure 8-1b). To rule out any effects of pH 
fluctuation in the medium, metabolic dependent adhesion mechanisms, and possible 
integrin participation, rosetting was performed in three different media: L-15 buffered 
with 5mM HEPES and 1% BSA, PBS with 0.05% NaN3, and L-15 buffered with 5mM 
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HEPES, 1% BSA and 5mM EDTA. As shown in Figure 8-1c, no difference was observed 
among all conditions tested, which confirmed that the strong adhesion mode depended on 
TCR-antigenic peptide-MHC recognition and was not an artifact of medium nor did it 
























Figure 8-1a. Percentages of naïve T cells rosetted with RBC coated with the indicated 























Figure 8-1b. Percentage of naïve T cells rosetted with RBC coated with indicated pMHC 
at three different site densities for 2 minutes incubation. Site densities were, 70μM - 250 


























Figure 8-1c. Percentage of naïve T cells rosetted with pMHC-RBC in different media for 
30 minutes. 
 
2. The strong adhesion mode is mediated by T cell surface molecules interacting with 
agonist pMHC only.  
 We have shown that T cells will develop strong adhesion for agonist pMHC 
coated RBC that is independent of integrins. However, RBC expresses many proteins on 
its surface in addition to the pMHC coated, including those that have not been identified 
and those the ligands for which were not yet known. To rule out any possible 
contributions from other molecules, streptavidin coated polystyrene beads were used to 
present pMHC to repeat the above experiment. Similar to the previous observation, 
agonist pMHC again resulted in a high percentage of rosettes, whereas null and 
antagonist pMHC did not promote rosette formation (Figure 8-2a). In order to test 
whether adhesion would increase upon introducing another ligand for T cell surface 
proteins, silica beads coated with biotinylated lipid bilayer were used in lieu of 
streptavidin coated polystyrene beads, which, after incubation with streptavidin, allowed 
coating of biotin tagged pMHC and GPI anchored ICAM-1, a known ligand for LFA-1 
on T cell (ICAM-1 liposome was provided by Tim Tolentino). Figure 8-2b and c show 
rosette percentages between T cells and silica beads before and after addition of ICAM-1. 
As shown on the figures, agonist pMHC had a significant percentage of rosette formed 
before addition of ICAM-1, where antagonist formed about the same rosette percentage 
of null pMHC, which was the background level. Upon addition of ICAM-1, the rosette 
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percentage reached 100% for agonist and significant increases were observed for null and 
antagonist pMHC. Together with the above results, we show that the strong adhesion 
mode is mediated only by pMHC binding of T cell surface proteins, which can 





















Figure 8-2a. Rosette percentage of naïve T cells incubated with pMHC coated 




















Figure 8-2b. Rosette percentage of naïve T cells incubated with pMHC coated on 1% 






















Figure 8-2c. Rosette percentage of naïve T cells incubated with pMHC and ICAM-1 
coated on 1% biotin lipid coated silica beads for 30 minutes. 
 
3. Quantify the effects of inhibitors on the strength of the strong adhesions. 
 In order to quantify the adhesion strength between a T cell and an agonist pMHC 
coated RBC, a micropipette adhesion strength experiment was designed. In this 
experiment, a micropipette of 3 μm inner diameter at the mouth was used to aspirate a T 
cell and the suction pressure was adjusted to 5 mm of H2O height. A T cell and a RBC 
were placed into contact for a minute and the pipette holding the T cell was then pulled 
away with a speed of ~1 μm/s. If the adhesion between the two cells was strong enough, 
i.e., exceeding 350 pN (= π/4 × 3 (μm)2 5 mm H2O), the T cell would be pulled off from 
its holding pipette. The percentage of pull-off is plotted in figure 8-3. Without any 
inhibitors, 75% of the T cells developed sufficient adhesion strength for them to be pulled 
off from the pipette, indicating their adhesion for agonist pMHC coated RBC exceeded 
350 pN, an order of magnitude higher than the typical strength of a single bond at the 
range of loading rates used (20 pN/s). Previous results have shown that this adhesion up-
regulation is mediated by T cell surface molecules interacting with pMHC only. To 
assess the contribution from CD8, another CTL surface protein that can bind MHC beside 
TCR, T cells were preincubated with CD8 blocking antibody, CT-CD8α. Incubation with 
CT-CD8α resulted a 7.5-folds reduction in the pull-off rate to a level similar to that when 
blocked by soluble agonist pMHC tetramer (Figure 8-3 second and third column), 
indicating that CD8 participates in this strong adhesion upon TCR antigenic peptide 
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recognition. Inhibitors to actin polymerization, latrunculin A (2 μM), and membrane 
rafts, Methyl-β-cyclodextrin (30 mM), were then tested. They were found to reduce the 
pull-off rate to levels comparable to those treated with the anti-CD8 blocking antibody 
and soluble agonist pMHC tetramer, suggesting that the strong adhesion mode is actin 
dependent and associated with membrane rafts. Three inhibitors targeted different 
components of signaling pathway were also tested and found to reduce the pull-off rate 
by almost half. Genistein, a broad PTK inhibitor, seemed to reduce the pull-off rate 
slightly more than PP2, an inhibitor to Src family of protein tyrosine kinases, and 



































Figure 8-3. Various inhibitors affect the adhesion strength between a naïve T cell and an 
agonist pMHC coated polystyrene bead. Tetramer – soluble agonist pMHC tetramer, LA 
– latrunculin A, MbCD – Methyl-β-cyclodextrin, Geni – genisterin, Wort – wortmannin.  
 
4. Monitoring the adhesion mode change within the first ten seconds of TCR/pMHC 
recognition.  
 We have shown in previous chapter that in hypotonic medium TCR bound to 
agonist and antagonist pMHC weakly with similarly low affinities and that CD8 did not 
contribute to binding of T cells to pMHC coated RBC. In isotonic medium, however, 
agonist, but not antagonist, pMHC induced strong adhesion to T cells that includes a 
significant contribution of CD8 and can be inhibited by disruption of actin cytoskeleton, 
membrane rafts, as well as tyrosine and lipid phosphorylation. Therefore, there must be a 
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TCR triggered, signaling required transition from CD8 independent weak adhesion to 
CD8 dependent strong adhesion. Here, we take advantage of micropipette adhesion assay 
to explore initial adhesion within the first 10 second of a T cell in contact with pMHC. 
Similar to previous kinetic measurement, a T cell and a pMHC coated RBC was held 
respectively by two glass micropipettes. They were put into contact for a predetermined 
amount of time as indicated on Figure 8-4a before one pipette was retracted to separate 
the two cells. This experiment was done in isotonic medium, in which the T cell would 
adhere to the RBC with a large area of continuous attachment if it was coated with as 
high a site density of agonist pMHC as those used in the previous kinetic measurement in 
hypotonic medium. Therefore the site densities were lowed by 1-2 orders of magnitude so 
that even at the longest contact time, 10 second, the resulted adhesion would still remain 
isolated point attachments mediated by single bonds between a TCR (and/or a CD8) and 
a pMHC. RBC coated with 12 sites/μm2 of agonist pMHC was used to generate the 
binding curves in figure 8-4a and b from two different experiments. Each point in the 
figures represents a mean ± s.e.m. of adhesion frequency estimated from 5 pairs of cells 
with 50 repeated contacts each pair. The contact times were chosen to have 0.25 s 
increment for the first 2 seconds to provide better temporal resolution. Both experiments 
obtained sigmoidal binding curves. The initial adhesion was low but remained stable for 
the first few contact times. Between 0.5-1 second, the adhesion frequency suddenly 
jumped to a much higher level and then stayed at that plateau level for the longest contact 
time tested (5 and 8 s). While the binding curves from the two experiments exhibit the 
same sigmoidal shape, their stable states (i.e., the two plateaus) and perhaps the transition 
from the initial to the final state, show different levels and time (Figure 8-4a, b). The 
higher plateau levels and earlier transition of the binding curve shown in Figure 8-4b 
correlates with the higher site densities of TCR and CD8 (80 and 668 μm-2, respectively) 
from the T cells used than those used to generate the binding curve shown in Figure 8-4a 
(74 and 530 μm-2, respectively). The same batch of RBCs coated with the same density of 






















Figure 8-4a. Adhesion frequency between T cell and agonist pMHC coated RBC in 























Figure 8-4b. Adhesion frequency between T cell and agonist pMHC coated RBC in 
isotonic media. The site densities of TCR and CD8 were 80 and 668 μm-2, respectively. 
 
5. The adhesion mode change is affected by anti-CD8 blocking antibody and other 
inhibitors. 
 We have observed a new type of binding curves that are quite different from the 
typical binding curves observed from the previously kinetic measurement using the same 
adhesion frequency assay. Instead of a simple convex curve that can be well fitted by the 
exponential Eq. 5-2, the nearly step-function type of sigmoidal curve cannot be described 
by the kinetic mechanism of second-order forward, first-order reverse, single step 
bimolecular reaction to form monomeric bonds. A more complex kinetic mechanism is 
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required, with multiple binders contributing to two different stable phases in the binding 
curve, a lower frequency phase and a higher frequency phase with the rapid transition 
around 0.75 second. We would like to further examine what factors might regulate the 
various features of such binding curve. From previous experiment, we know that anti-
CD8 blocking antibody and several inhibitors are able to inhibit the strong adhesion 
between T cell and agonist pMHC coated RBC. We therefore tested their effects on the 
high plateau level of the binding curve using a single contact time point of 5 second. The 
anti-CD8 blocking antibody, CT-CD8α, completely blocked adhesion - the detected ~1% 
background was the same as TCR interaction with null pMHC. Genistein and latrunculin 
A also reduced adhesion partly. These findings suggest that there is an up-regulation of 
CD8/pMHC interaction upon TCR antigenic peptide recognition. Without it, the adhesion 
remains at low level. However, 1% of adhesion frequency after CT-CD8α blocking is 
significant lower than the adhesion frequency at the initial phase showed in figure 8-4a 
and b. This suggests that there is probably already some synergistic effect between TCR 
and CD8 at that initial phase. However, due to temporal resolution, we could not observe 
the transition. Later, as contact time increase, there is second increase in adhesion 
frequency. Together, these results suggesting that there are probably multiple steps from 
simple TCR/agonist pMHC interaction to evolve into massive adhesion, and current 
resolution only allows us to dissect two steps. When other two CD8 blocking antibodies 
that we used in previous chapter were tested again in isotonic condition, we found that 
53-6.7 was still not able to block the adhesion where 5H10 could (figure 8-5b). We 
concluded that 53-6.7 does not interfere with CD8 binding.  CT-CD8α has been shown to 
have a binding epitope located on CDR2 loop of the CD8α [130], therefore it interferes 






















Figure 8-5a. Various inhibitors affect the adhesion frequency between naïve T cells and 
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Figure 8-5b. Adhesion comparison of T cell interacting with pMHC with or with CD8 
blocking antibodies at contact time 5 second. 
 
6. Antagonist pMHC also show synergistic effect with CD8 binding.  
 We have shown that antagonist pMHC is not able to promote strong adhesion at a 
site density 30 times of the agonist pMHC which generates strong adhesion. It is 
therefore concluded that there is only weak adhesion between T cell and antagonist 
pMHC. However, when we repeated the adhesion frequency test using RBC coated with 
600 sites/μm2 antagonist pMHC by high temporal resolution of 0.25 s contact time for the 
first 2 seconds, we observed the same sigmoidal curve as in section 4 (figure 8-6a). 
Subsequent blocking experiment shows that CT-CD8α antibody completely blocked the 
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second phase adhesion at 5 s to the level of the first phase adhesion at 0.25 s, which is the 
same for background level (figure 8-6b). We therefore conclude that although antagonist 
























Figure 8-6a. Adhesion frequency between T cell and antagonist pMHC coated RBC at a 






















Figure 8-6b. CD8 blocking antibody, CT-CD8α, reduce adhesion frequency between 
naïve T cells and antagonist pMHC coated RBC to background level. 
 
7. Tetramer binding was not affected by inhibitors. 
 By linking 4 pMHC monomers on one streptavidin molecule, tetramer pMHC has 
a higher avidity and a significant slower dissociation rate than monomers in binding to 
TCR.  It has become a useful tool for staining T cell based on TCR antigenic specificity, 
 74
especially in identifying peripheral T cells. It has also been used to evaluate the role of 
coreceptors CD4 and CD8 in TCR/pMHC binding, from which controversial results were 
obtained. 
 To further test the hypothesis that engagement of TCR with agonist pMHC 
triggers actin cytoskeleton- and membrane raft-dependent signaling that results in 
upregulation of CD8 binding to pMHC, we analyze tetramer pMHC binding to T cells 
using flow cytometry in the absence or presence of anti-CD8 mAbs and other inhibitors 
over four decades of tetramer concentrations, ranging from 0.001 μg/ml to 10 μg/ml. For 
blocking experiments, Latrunculin A, methyl-β-cyclodextrin, Wortmannin and two CD8 
blocking antibodies, 5H10 and CT-CD8α, were added to T cells prior of adding tetramer. 
For each inhibitor, two different incubation conditions were tested, 0°C with sodium 
azide to prevent receptor internalization or 25°C without sodium azide. Null pMHC 
tetramer was used as background control for every agonist pMHC tetramer concentration 
used. A set of phycoerytherin (PE) fluorescent calibration beads was used for each 
experiment to convert mean fluorescent intensity into number of PE molecules bound per 
cell (PEBC). Surprisingly, none of the inhibitors tested significantly reduced the tetramer 
binding and tetramer binding was not affected by possible receptor internalization as 
there was no difference between the binding curves acquired at 0°C with sodium azide 
and the ones acquired at 25°C without sodium azide (figure 8-7 a-e). Thus, the transition 
to strong adhesion observed when pMHC was presented by a surface does not occur 




















Figure 8-7a. Lack of effect of Latrunculin A on agonist pMHC tetramer binding to naïve 






















Figure 8-7b. Lack of effects of methyl-β-cyclodextrin and wortmannin on agonist pMHC 






















Figure 8-7c. Lack of effects of CD8 blocking antibodies, 5H10 and CT-CD8α, on agonist 






















Figure 8-7d. Lack of effects of methyl-β-cyclodextrin and wortmannin on agonist pMHC 






















Figure 8-7e. Lack of effects of CD8 blocking antibodies, 5H10 and CT-CD8α, on agonist 
pMHC tetramer binding to naïve F5 T cells at 25°C. 
 
Discussion 
 Upon engagement to pMHC, TCR recognize different antigenic peptides that 
incorporated to MHC and generate distinct signal. Together with its coreceptor and other 
accessory molecules, they will orchestrate different response to antigen. In contrast to the 
kinetic and affinity data obtained in hypotonic media (preceding chapter), which are at 
odds with this conceptual framework, results from both micropipette and resetting 
experiments performed in isotonic media are consistent with this framework. In 
physiological conditions, T cells develop strong adhesion for agonist-MHC on RBC but 
not to null or antagonist pMHCs. This adhesion is mediated by TCR-CD8/pMHC only 
and is independent of other molecules. The change in adhesion mode happens around 
0.75 second after TCR in contact with pMHC and can be completely blocked by CD8 
blocking antibody and can be reduced by inhibiting protein tyrosine kinase (PTK) 
activation, disrupting actin polymerization, and dissolving membrane rafts.  
 CD8 as a coreceptor has been shown to be important in T cell activation by 
coupling TCR/CD3 to raft-associated Lck [108, 129, 131], although the exact mechanism 
is still not clear. Early kinetic studies using SPR reveal controversial result about 
cooperative binding between TCR and CD8 to pMHC. It was first shown that CD8 
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enhances formation of stable TCR/MHC I complexes by reducing off rate [106]. Later, 
Wyer et al. show that TCR and CD8αα bind pMHC independently [105]. However, 
many experiments involving T cell clones or transgenic T cells seam to support the idea 
that CD8 facilitate ligand recognition [116, 117, 132]. Mescher’s group has shown that 
upon the addition of anti-TCR mAb in solution (fluid-phase), where only bivalent cross-
linking of the TCR is presumed to occur, CTL are stimulated to undergo CD8-dependent 
adhesion to class I MHC. CTL binding to irrelevant class I MHC could also be achieved 
by this TCR cross-linking method and can be blocked by CD8 antibody too [111]. 
Furthermore, the TCR-dependent activation of CD8 requires protein tyrosine 
phosphorylation, as shown by the ability of herbimycin A and genistein to inhibit 
triggered adhesion to class I MHC [114]. Recently the same group used wortmannin, a 
potent PI3 kinase inhibitor, blocks TCR-signaled activation of CD8-mediated adhesion to 
class I MHC protein [115]. They suggested that activation of fyn-associated PI3K is 
downstream of TCR-dependent activation of PTK in the signaling pathway that leads to 
up-regulation of CD8-dependent adhesion.  
 However, our results reveal a more complicated mechanism. We observed 
massive adhesion occur only on agonist pMHC not null or antagonist pMHC and CD8 
blocking antibody can effectively block this massive adhesion (figure 8-1a, 7-2a and b). 
Other disruption agents can also affect this, like genistein, latrunculin A and methyl-β-
cyclodextrin (figure 8-3). This massive adhesion developed at a very short time – within 
the shortest 2 min time resolvable by the resetting experiment and also seen in 1 min in 
the micropipette pull-off experiment. This is much shorter than what Mescher group 
observed (30 minute to 2 hour) and at a higher percentage than they reported (nearly 
100% for resetting and 75% for micropipette compared to 20%) (figure 8-1a and figure 8-
3). Antagonist is not capable of mediating CD8 up-regulated strong adhesion (7-1a, 7-2a 
and b). However, when we examined the initial contact between T cells and antagonist 
pMHC coated RBCs using micropipette adhesion frequency assay, we noticed that the 
binding curve exhibit a sigmoidal shape with threshold around 0.75 second (figure 8-6a). 
Consequent CD8 blocking antibody experiment showed that this increase in adhesion 
probably is mediated by CD8 (figure 8-6b). Therefore, antagonist is also capable of CD8 
cooperative binding but not developing this weak adhesion into a strong adhesion. On the 
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other hand, initial contact test between T cells and agonist pMHC coated RBCs revealed 
that adhesion followed a stepwise increase with a threshold around 0.75 second and 
possible another before 0.25 second, which exceeds our temporal resolution (figure 8-4a 
and b). This initial weak adhesion could eventually developed into a strong adhesion if 
enough contact time between a T cell and an agonist coated RBC was allowed (figure 8-
1a).  
 In studying the mechanism of TCR dependent CD8 up-regulated adhesion, 
Mescher’s group suggested that activation of fyn-associated PI3K is downstream of 
TCR-dependent activation of PTK in the signaling pathway that leads to up-regulation of 
CD8-dependent adhesion [114, 115]. In collaboration with Dr. Sambhara from CDC, we 
showed that only agonist was capable of activation PI3K not antagonist, yet in short 
contact time, which no one were able to examine before, they both were able to mediate 
CD8 binding (figure 8-8). Therefore, other signal pathway must play a role in this initial 
CD8 cooperative binding.  
 
 
Figure 8-8. Western blot of phosphorylated Akt (common marker for PI3K activation) on 
SDS-page loaded with whole T cell lysates after incubated with different peptide load 
macrophages for indicated time. (Courtesy of Dr. Karen Hill-Williams from Dr. 
Sambhara’s lab in CDC.)  
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Tetramer pMHCs have been applied to study the interaction among TCR, 
coreceptor and pMHC and controversial results have been shown regarding the role of 
coreceptors. Using class II MHC dimmer, similar to tetramer in enhancing avidity and 
reducing off rate between TCR and MHC, Hamad et al found that CD4 does not play any 
significant role in stabilizing pMHC-TCR interaction as it fails to enhance binding of 
dimeric pMHC to specific T cells or influence pMHC-TCR dissociation rate or TCR 
downregulation [133]. Using either CD4+ and CD4- T cell clones or CD4 blocking 
antibody, two groups have separately shown that CD4 is important in IL-2 secretion or 
pH change due to T cell activation. However, neither group noticed any change in 
tetramer binding, indicating that CD4 is not important in pMHC binding yet is necessary 
in T cell activation possibly through a another mechanism [134, 135]. Recently, Daniels 
et al. showed that CD8 is not only important in T cell activation but also TCR-pMHC 
tetramer binding [136]. Using engineered pMHC mutant tetramers that retain faithful 
interactions with cognate TCR but bind CD8 with either reduced or enhanced affinities, 
Wooldridge et al. showed that pMHC/CD8 interaction can significantly affect the decay 
of soluble pMHC from the CTL surface. When using CD8 blocking reagents to study the 
role of CD8, different groups used different blocking antibodies with different incubation 
temperature and conditions, which made it very difficult to assessment the results. For 
example, some researchers showed that antibody 53-6.7 enhanced tetramer binding [130]. 
However, we showed in previous chapter that this antibody did not have any inhibitory 
effect in micropipette experiment performed in hypotonic media. Two other anti-CD8 
antibodies, 5H10 and CT-CD8α, inhibited binding completely in rosetting and 
micropipette pull-off experiments performed in isotonic media. In tetramer binding 
experiments performed in isotonic media, we selectively used some of the inhibitors that 
were shown potent in inhibiting pMHC binding to TCR and tested their effects on 
tetramer binding systematically. Interestingly, they failed to block tetramer binding in all 
cases. To rule out the possibility of TCR internalization after the application of inhibitors, 
site densities measured by flow cytometry with or without inhibitors were compared in 
figure 8-9, which show no differences. These results confirmed our observation that CD8 






















Figure 8-9a. Site density comparison of TCR and CD8 (stained with CT-CD8α) with or 























Figure 8-9b. Site density comparison of TCR with or with CD8 blocking antibody (CT-
CD8α) at different temperature, 0°C with sodium azide to prevent receptor 



















2 ) 0 degree
25 degree
 
Figure 8-9c. Site density comparison of CD8 (stained with CT-CD8α) at different 
temperature, 0°C with sodium azide to prevent receptor internalization or 25°C degree 
without sodium azide.  
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CHAPTER IX 
SUMMARY AND RECOMMENDATION FOR FUTURE STUDIES 
 
Introduction 
 Early kinetics studies of CD16 and TCR interacting with respective ligands 
revealed some unexpected features of binding properties. The quest for investigating part 
of these features was outlined in the specific aims stated in chapter I, leaving new venues 
of investigation for future study.  
 
Ligand binding properties of CD16 
 Ligand binding properties of CD16 has been intensively studies by us and many 
other groups using various forms of CD16 and assays. Existing data revealed some 
interesting findings. Our lab has previously showed that CHO CD16aTM and CHO 
CD16aGPI have different affinity and kinetics for the same ligand, IgG, despite that fact 
that they have exactly the same extracellular domain, and the effect is reversed for IgG 
from different species. It was suggested that receptor membrane anchor causes this effect 
by altering the receptor conformation. We have now expanded this observation from 
CD16a to CD16b. We have shown a correlation between affinity and molecule anchor 
length, and depending on the ligand species such correlation can be either positive or 
negative. We have also shown that glycosylation is important in regulating binding 
affinity, raising question for some data generated using only the extracellular domain of 
an aglycosylated receptor: Are they really measure the intrinsic affinity and kinetics of a 
receptor ligand binding?  
The real-time flow cytometry methods developed in this thesis is most suitable to 
study binding of cell membrane receptors to soluble ligands, as in the case of CD16 and 
soluble hIgG1 binding. It allows us to mesure ligand binding affinity and kinetics in the 
native environment of the receptor. Other 3D assays may have to compromise the native 
environment of the molecules. Recently, this method has been applied to study TCR 
organization on cell membrane using dimeric pMHC-Ig. Results revealed that TCR on 
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activated T cells were preferably organized in dimeric form whereas TCR on naïve T cell 
were preferably organized in monomeric form. Real-time flow cytometry can also be 
modified by adding competition binding into the assay, which may be more robust in 
measuring some other molecular interactions.  
Our results suggeste a probable long range conformational change upon anchor 
truncation and indicate the effects of glycans. Molecular simulation may provide a power 
tool to simulate the possible conformational changes and glycan binding since no crystal 
structures for the membrane anchors and for glycorsylated CD16 are available yet. 
 The ability to regulate affinity the receptor anchor and glycosylation could be 
important in ligand binding and signaling transduction as suggested by some of in vivo 
studies. The exact mechanism of how outside signal of ligand binding is converted into 
inside signal and how CD16 expressing cells are able to discriminate different isotypes of 
IgG remain unknown. Not only is membrane anchor important in regulating ligand 
binding as we showed here, but it is also important in association with ITAM containing 
signaling chains, like γ and ζ chains for CD16aTM. What is more important is how GPI 
anchored molecule generates signals. It is believed that they do so by associating with 
other signaling motif containing Fcγ receptors, like CD32aTM. How ligand binding leads 
to molecular association and vice versa and how association generates signal are not 
known.  
 
2D and 3D kinetics 
Most of the data reported in this thesis were generated by micropipette adhesion 
frequency assay. This assay measures receptor ligand binding on two apposing 
membranes and evaluates 2D kinetics parameters using a probabilistic model. Another 
method for 2D kinetic measurement is fluorescent recovery after photo bleach (FRAP). 
In this method, a receptor expressing cell is placed on a glass-supported lipid bilayer, 
which replaces one cell membrane in the micropipette assay. It measures kinetics in a 
diffusion coupled reaction process and also results in 2D kinetics parameters. In SPR and 
real-time flow cytometry measurements, one of the binding partners is placed in solution. 
Molecules in 2D and 3D bind with different association rate constants and affinities, 
move with different degrees of freedom, and change different amount of entropy upon 
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binding [137]. From Table 4-1, one can see that there exist many discrepancies between 
2D and 3D measurements. At present, there is no established method to convert affinity 
and kinetic parameters acquired from 3D to 2D measurements because not until recently 
have 2D parameters become experimentally measurable [118]. To solve this problem, 
two different measurements, 2D and 3D, on exactly the same molecule, including 
molecular anchor and glycosylation, are necessary. 
 
TCR antigenic pMHC recognition 
T cells can discriminate antigen peptides from other peptides that differ as little as 
a single amino acid and launch very distinct responses toward APC.  How do T cells 
fulfill this is still poorly understood. Several models have been proposed, which deal with 
various aspects of T cell discrimination, including affinity model [87], conformational 
change model [88, 89], dimerization or oligomerization model [90, 91], kinetic proof-
reading [92] or kinetic discrimination model [93], kinetic/segregation model [94, 95] and 
peptide stability model, etc. So far no direct evidence has been found to support the 
conformational change model. For the dimerization model, several groups have shown 
that crosslinked pMHC can induce TCR dimerization or oligomerization [135, 138]. 
However, discrepant results have been reported on soluble TCR oligomerization studies: 
Baker et al. [96] cannot reproduce the result published by Reich et al [90]. Further more, 
no evidence has been obtained to support the notion of TCR dimerization or 
oligomerization on cell membrane upon binding of pMHC. Recently emerged peptide 
stability model highlights the interaction between peptide and MHC as an important 
factor in determining the outcome of T cell-APC contact. In this model, partial agonist 
can be generated through changing peptide affinity for MHC [97]. Other models suggest 
that discrimination may be based on the parameter(s) of the TCR-pMHC interaction. The 
general approach is to measure parameter(s) of the same TCR interacting with the same 
MHC that is complexed with several peptides known to trigger different T cell responses 
and examine the correlation (or the lack thereof) between the parameter values and the 
levels of T cell activation. The affinity model argues that TCR-pMHC binding affinity is 
the key parameter that regulates the TCR activation. It is difficult to explain how small 
variations in affinity among the different pMHCs interacting with the same TCR may 
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give rise to a wide range of variations in cellular responses. Kinetic proof-reading and 
kinetic discrimination models suggested that kinetics, especially the dissociation rate 
constant, is the key regulator. Through a serial signal transduction kinetic scheme, 
moderate differences in off-rates of TCR/pMHC interactions can be amplified to 
sufficient large to give rise to a threshold-type of response curve for T cell activation. The 
kinetic/segregation model further extends the kinetic proof-reading or kinetic 
discrimination model. It proposes that the segregation induced by kinetic difference 
between TCR and different pMHC is the determinant for TCR triggering. The 
mechanism of T cell discrimination and the initiating mechanism of T cell signaling may 
be related. Segregation by size of the TCR-pMHC bond, which excludes phosphotases 
such as CD45 (check out whether this statement is true), has been suggested as a 
mechanism for T cell signaling and also for discrimination.  
All these arguments are focused on the affinity and kinetics of TCR binding to 
peptide-MHC. Because the experimental data for off-rates of TCR-pMHC are most 
available and correlate with T cell activation, the kinetic proof-reading model has been 
the most popular model so far. Though there are a few outliers in the correlation between 
half-life and potency to trigger T cell activation, it can be corrected if enthalpy is used. 
Considerations of other requirements for T cell discrimination also place constraints on 
the above models, for example, the positive and negative selections that determine the T 
cell repertoire, the substantial differences in the densities of self-peptides and antigen 
peptides, etc. 
In our experiments, antigenic discrimination can be detected at the level of 2D 
binding between T cells and surfaces (RBC, polystyrene and silica beads) that are 
functionalized with pMHC only and be assayed by adhesion experiments (micropipette 
adhesion frequency test, pull-off test, and rosetting). Contributions from selectins, 
integrins, cadherins and other molecules are excluded through control experiments where 
either EDTA was used to inhibit cation-dependent adhesion or RBCs were replaced by 
polystyrene or silica beads. Thus, pMHC is sufficient and other molecules from APC are 
not required for discrimination at the level of adhesion.  
Antigenic discrimination has no less than two components. The first requires TCR 
binding to pMHC but not CD8 and the second requires both TCR and CD8 binding to 
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pMHC, hereafter referred to as CD8 independent and CD8 dependent binding and 
discrimination. In the present experiment, the participation of CD8 was blocked by 
incubating T cells with a CD8-blocking monoclonal antibody that bind to pMHC-binding 
epitope of the CD8. However, the antibody used is a full antibody and it may cause a 
possible crosslink of two CD8s by two Fab arms. Therefore, other means of inhibiting 
CD8, which will not introduce possible crosslink or steric hinder are worth checking. For 
example, using α3 domain mutants of pMHC-I complexes to suppress CD8 binding to 
MHC-I as suggested by Xu et al [139]. TCR binding precedes CD8 dependent binding. 
However, we do not know if CD8 only binds to the same pMHC that is engaged by TCR 
or an unengaged pMHC. In other experimental system, people have shown that activation 
of TCR by a monoclonal antibody could lead to CD8 binding to an irrelevant pMHC 
[114]. On naïve T5 T cell surface, the number of CD8 molecules exceeds TCR by 5 
times. After TCR engagement, it is possible that CD8 bind to other pMHCs that are not 
engaged with TCR. A micropipette experiment with RBC presenting a mixed ratio of 
agonist and null pMHCs will allow us to investigate this. 
The micropipette binding curve with high temporal resolution revealed a 
sigmoidal curve instead of a typical hyperbolic curve with a low binding frequency phase 
before 0.75 second contact time and to a high binding frequency phase after 1 second and 
stayed at that level. In an effort to dissect the regulatory mechanisms, various agents were 
tested for their ability to block the high binding frequency phase. Signaling inhibitors, 
latrunculin A and methyl-β-cyclodextrin had partial effects. However, CD8 blocking 
antibody completely blocked the high binding frequency down to background level, 
which suggested CD8 binding results in a much higher adhesion frequency than the TCR-
pMHC binding. Unlike the TCR/pMHC interaction, which can be initiated as soon as the 
TCR is in physical contact with pMHC, CD8 binding has a ~1 second delay after which it 
binds with very rapid on- and off-rates. The combined effect of these two levels of 
binding is a sigmoidal binding curve. What are the kinetic mechanisms for the component 
interactions and for the overall reaction? And what are the kinetic rate and binding 
affinity constants for those? A simple two-step model can be constructed. The first step is 
TCR binding, which follows second-order forward, first-order reverse kinetic 
mechanism. The second step is CD8 binding, which requires no less than 0.75 second 
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TCR engagement to activate. Once activated, however, it binds with very rapid kinetics. 
Several parameters of interest can be determined by adding some experiments to the data 
already obtained: a) the binding affinities of TCR for agonist and antagonist pMHC in the 
CD8 independent binding and the difference between the two values, b) the putative 
upregulated binding affinities of CD8 for agonist and antagonist pMHC (assuming that 
the TCR binding is additive to the upregulated CD8 binding) and the difference between 
the two values, c) test the hypothesis that TCR binding is additive to the CD8 binding by 
measuring the adhesion frequenies corresponding to two different sets of densities of 
TCR and CD8, and d) determine whether or not the recruitment of CD8 in the second 
step amplifies the discrimination signal. The data obtained in this thesis suggest that T 
cells interacted with either agonist pMHC or antagonist pMHC displayed a sigmoidal 
binding curve. Mechanisms for upregulation of the CD8-dependent adhesion in the 
second phase of the sigmoidal binding curve may include conformational change that 
increases CD8 affinity or change in membrane organization that increases CD8 avidity. 
Since CD8-binding to null pMHC is undeteactable and to agonist pMHC follows after 
TCR binding, the CD8 binding must be induced by the TCR binding, which may involve 
inside-out signaling that changes CD8 and/or the cell membrane organization. Questions 
such as what triggers the transition from CD8-independent binding to CD8-dependent 
binding, how this transition is regulated, and how the parameters measured above 
correlate with the potency for different peptides to trigger T cell activation, need to be 
answered before we fully understand this phenomenon.  
The present results showed the CD8 dependent adhesion to agonist pMHC can be 
reduced by treatment with lutrunculin A, methyl-β-cyclodextrin, PP2, genisterin, 
wortmanin, but not by EDTA etc (spell out all items in the etc). It would be interesting to 
see if CD8 dependent adhesions to partial agonist and antagonist pMHCs are also 
regulated by the same treatments and what the signaling mechanisms that result in the up-
regulation of CD8 binding are, and how the discriminatory signals (differences in the 
parameters of binding to MHC complexed with different peptides) are affected by these 
agents. 
The CD8-dependent component of discrimination is eliminated and the CD8-
independent component of discrimination is greatly suppressed by hypotonic medium. 
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The apparent affinity of TCR for agonist pMHC is substantially reduced. More 
micropipette experiments on partial agonist and antagonist pMHC in isotonic medium 
will allow us to compare the differences of apparent affinities under isotonic and 
hypotonic condition. We still do not know the mechanisms for the effects of the 
hypotonic medium. Compared to the experiments that conducted in isotonic medium with 
varies inhibitors, hypotonic medium had effect similar to latrunculin A and methyl-β-
cyclodextrin on agonist. It is possible that hypotonic medium disrupt the proper TCR 
membrane organization so that when interacting with agonist pMHC, TCRs cannot 
aggregate and send out signal as usual. It will be ideal if we could test soluble TCR under 
micropipette to compare kinetic parameters with hypotonic data. It will allow us to 
determine if the kinetic parameters measured under hypotonic medium is intrinsic 
parameters. CD8 seems not to participate in binding in hypotonic medium, as several 
CD8 blocking antibodies did not decrease binding probability for agonist. More 
experiments on CD8 blocking need to be done on partial agonist and antagonist binding.  
The long-term binding of agonist pMHC tetramer to T cells analyzed by flow cytometry 
is CD8 independent and nonresponsive to lutrunculin A, methyl-β-cyclodextrin, and 
wortmanin. These data point out the inadequacy of using SPR data to understand the 
mechanism of T cell discrimination. The flow cytometry experiment uses T cells so it is 
more physiological than the BIAcore experiment that uses purified TCR, CD8, and 
pMHC. Yet flow cytometry experiment fails to detect the CD8 dependent binding and the 
regulatory effects of lutrunculin A, methyl-β-cyclodextrin, and wortmanin. It can 
therefore be concluded that CD8 dependent binding and the regulatory effects of 
lutrunculin A, methyl-β-cyclodextrin, and wortmanin cannot be revealed by SPR. The 
micropipette experiments are more adequate because a) very strong signals for 
discrimination (orders of magnitude differences) can be detected, b) at least two levels of 
discrimination (CD8 independent and CD8 dependent) can be dissected, c) the 
discrimination signals can be manipulated by treatments with hypotonic media and 
several regulatory agents, and d) the molecules reside in their native environment and all 
ingredients in the T cell are intact. Therefore, the reason why flow cytometry experiment 
did not detect CD8 dependent binding could be that surface presentation of pMHC is 
required to trigger CD8 depend binding. Although in the flow cytometry experiment, null 
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pMHC tetramer showed mean fluorescence intensity a little higher than T cells without 
incubation with any tetramer therefore was treated as background, it is necessary to 
perform flow cytometry experiment on partial agonist and antagonist pMHC tetramer to 
see if the flow cytometry experiment detect discrimination with similar levels of signal as 
in micorpipette experiment that performed in isotonic medium. In micropipette 
experiment, inhibitors such as lutrunculin A, methyl-β-cyclodextrin, and wortmanin only 
regulated the CD8 dependent binding. More micropipette experiments, where those 
inhibitors are present together with CD8 blocking antibody, are needed to investigate if 
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